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ABSTRACT 
 
Numerous tetrahydroisoquinoline alkaloids such as our target substance 
(-)-lemonomycin were found to show antimicrobial, antibiotical as well as 
cytotoxic activity against a versatile pool of microorganisms respectively tumor 
cell lines. As these potent therapeutics are found at a very low abundance in 
various natural resources, fermentation is not regarded as an acceptable source. 
The goal of synthetic chemists is to provide the scientific medicinal community 
with short and cheap approaches to the desired compounds. Not only the low 
availability of these substances but also the opportunity to create a diversity of 
structural derivatives have been a reason for numerous chemists to work on this 
challenging research topic. 
 
Within this thesis our recent synthetic efforts are reported. Based on a former 
synthetic approach we started our investigation ending with an alternative route 
which allowed us to gain a highly functionalized intermediate of lemonomycin. 
The derived tetrahydroisoquinoline building block was established by an 
enantioselective alkylation reaction via Corey-Lygo phase transfer catalyst 
followed by a substrate controlled stereoselective Pictet-Spengler cyclization as 
key steps of this synthesis. All present stereogenic centers were set correctly in 
the regard of the corresponding chiral centers in the natural compound. 
 
xii 
 
ZUSAMMENFASSUNG 
 
Zahlreiche Vertreter der Tetrahydroisoquinoline Alkaloide, wie auch 
Lemonomycin selbst, zeigen sowohl antimikrobielle, antibiotische als auch 
cytotoxische Eigenschaften. Auf Grund ihrer medizinischen Wirksamkeit sind 
diese Substanzen für die Medizin und somit auch für den Chemiker von großer 
Wichtigkeit. Ihre Konzentration in der Biomasse ist äußerst gering, weswegen 
Fermentation zu ihrer Gewinnung nicht in Frage kommt und somit nur ein 
synthetischer Zugang zu den potentiellen Therapeutika in Frage kommt. Aufgabe 
der Chemie ist es, möglichst kurze und kostengünstige Synthesen zu entwickeln 
um genügend Material für pharmakologische Test und zur späteren 
Medikamentierung bereitstellen zu können. Besonders ist darauf hinzuweisen, 
dass es durch den synthetischen Zugang möglich ist, Derivate zu erzeugen, 
deren Wirksamkeit oft höher ist als die des jeweiligen Naturstoffs selbst. 
 
In dieser Arbeit sind kürzlich errungene Fortschritte im Bezug auf die 
Totalsynthese von Lemonomycin dokumentiert. Ausgehend von billigen 
Startsubstanzen war es möglich ein hochfunktionalisiertes Intermediat des 
Naturstoffs herzustellen, in dem alle Stereozentern, die auch später in der 
Zielsubstanz enthalten sind, die korrekte Konfiguration besitzen. Als 
Schlüsselschritte dieser Synthese wurde eine enantioselective Alkylierung eines 
aromatische Bausteins mit dem heterogenen Phasentransferkatalysator nach 
Corey-Lygo als auch, die für die Substanzklasse der Tetrahydroisoquinoline 
typische, Pictet-Spengler Zyklisierung gewählt. Das zur weiteren Verarbeitung 
angedachte Produkt wurde mit guter Ausbeute und exzellenter optischer Reinheit 
hergestellt. 
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INTRODUCTION 
 
Since the isolation and structure elucidation of naphthyridinomycin in 1974, 
tetrahydroisoquinoline antitumor antibiotics have been under intense 
investigation. Today about 60 compounds of this substance class have been 
isolated. This natural occurring alkaloids form three families, according to their 
specific structural features; the saframycin, the naphthyridinomycin/bioxalomycin 
and the quinocarcin/tetrazomine family. 
Besides their fascinating and challenging structural characteristics, the 
antitumor and antimicrobial behavior of numerous potent cytotoxic 
tetrahydroisoquinolines have been reason enough for these substances to serve 
as attractive synthetic drug targets during the last three decades. 
Chemistry, biology and syntheses of members of the quinocarcin family 
are topic of this work with an emphasis on the efforts towards an enantioselective 
total synthesis of (-)-lemonomycin. 
 
NH
N
OH
O
O
O
OH
OH
O
N
OH
O
(-)-Lemonomycin (1)  
Figure 1. (-)-Lemonomycin 
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Tetrahydroisoquinoline Antitumor Antibiotics 
 
As already mentioned in the introduction, the tetrahydroisoquinoline 
alkaloids consist of three families. The largest is the saframycin family, containing 
the saframycins (2), renieramycins (3), safracins (4) and ecteinascidines (5).1,2 
Five condensed six-membered rings form the common pentacyclic framework of 
this subgroup. The two terminating rings either exist as quinones and/or 
hydroquinones, additional common structural features are a 
tetrahydroisoquinoline moiety and a piperazine ring, sharing one of its nitrogens 
with the neighboring piperidine subunit (Figure 2). Fukuyama and Sachleben 
were the first chemists to publish a total synthesis of a saframycin congener with 
racemic saframycin B in 1982.3 
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O
O
O
N
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Figure 2. The Saframycin Family 
 
A second very important family is the naphthyridinomycin family. 
Naphthyridinomycin itself was long believed to be a natural occurring 
tetrahydroisoquinoline alkaloid as it was isolated by Kluepfel et al. in 1974 from 
Sreptomyces lusitanus,4 but repeated attempts to isolate this compound under 
the original as well as under milder conditions failed and only a congener 
3 | P a g e  
 
bioxalomycin β2 was isolated,5 indicating that naphthyridinomycin might only arise 
from the opening of the labile oxazolidine moiety due to a too harsh isolation 
procedure. Treatment of the fermentation broth of Streptomyces lustianus with 
sodium cyanide led to a more stable congener of naphthyridinomycin, 
cyanocycline A,6 an old acquaintance in the research group of Mulzer.2 Together 
with the dnacins and aclindomycins this family is complete, containing a main 
carbon frame work of five to seven condensed rings, four of which are six-
membered and one to three five-membered ones (Figure 3). 
 
 
Figure 3. The Naphthyridinomycin Family 
 
The quinocarcin family is the third and last family of this exciting alkaloid 
pool, with quinocarcin (8) itself, quinocarcinol (10), tetrazomine (9) and 
lemonomycin (1) found as natural occurring congeners (Figure 4). A penta- or 
tetracyclic main carbon core is present, bearing the characteristic isoquinoline 
moiety, whose aromatic ring can either exist as hydroquinone or quinone ring, 
condensed to a pyridine moiety. Isolation, structure elucidation and biological 
activity of lemonomycin will be discussed in more detail within the next pages. 
 
 
Figure 4. The Quinocarcin Family 
 
A large number of the above mentioned natural products and some of their 
derivatives show potent cytotoxic, antibiotic and antimicrobial activities and are 
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therefore of big interest for medicinal and synthetic chemists. 
Tetrahydroisoquinoline antitumor antibiotics themselves and related synthetic 
products may serve as various therapeutics. 
 
 
The Quinocarcin Family 
 
Isolation and Structure Elucidation 
 
Quinocarcin (8) and quinocarcinol (10) (Figure 5) were both isolated from 
Streptomyces melanovinaceus nov. sp. by Tomita et al. in 1983.7 Quinocarcin 
was found to have in vitro activity against Gram-positive bacteria and even 
showed antitumor activity against murine tumors. X-ray crystallography was used 
to determine the structure of qinocarcinol,8 whereas the structure of quinocarcin 
was determined by comparison of the NMR-data of both natural products,9 which 
could be confirmed by reductive conversion of the natural product into 
quinocarcinol. Nine years later, when Garner’s asymmetric total synthesis of 
(-)-quinocarcin was published,10 scientists were able to determine the absolute 
configuration. Through its isolation, many chemists such as Danishefsky,11 
Fukuyama12 and Weinreb,13 just to mention a few of them, have contributed 
efforts and total syntheses to this research topic. Some years ago, the sole total 
synthesis of this potent broad spectrum antibiotic was published by Stoltz et al.,14 
affirming, that this group of natural products still is in the aim of the scientific 
society. 
 
 
Figure 5. Quinocarcin and Quniocarcinol 
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Eight years after the isolation of quinocarcin, Suzuki et al. reported the 
isolation of tetrazomine (9) (Figure 6) from Saccharothrix mutabilis subsp. 
chichijimaensis in 1991.15 Its structure was elucidated by spectroscopic methods, 
mainly relying on two dimensional NMR-data.16 The pentacyclic core framework 
is very similar to the carbon skeleton of quinocarcin, but the unusual substitution 
on C10’, an amino acid(3-hydroxy pipecolic acid), is unique for tetrazomine. The 
relative and absolute configuration of the tetrazomine and its aminosugar 
moiety17 were determined by Williams et al., within the invention of the first total 
synthesis18,19 of this quinocarcin congener. 
 
 
Figure 6. Tetrazomine 
 
Besides two other antibiotic compounds, lemonomycin hydrochloride was 
isolated from 2000 liters of fermentation broth from Streptomyces candidus (LL-
AP191). Treatment with aqueous sodium hydroxide revealed the natural product, 
which was extracted with chloroform. Finally, lemonomycin was precipitated from 
acetone as “lemon-yellow spheres”, bringing its discoverers to baptize it 
lemonomycin. Although lemonomycin (1) was already isolated in 1964 from 
Streptomyces candidus (LL-AP191) and some of its structural features, such as 
the quinone moiety, could be affirmed by IR- and NMR-spectra,20 its structure 
was determined by He et al. in 2000.21 
 
 
Figure 7. Lemonomycin and Fragments 
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Belonging to the quinocarcin family of tetrahydroisoquinoline antitumor 
antibiotics, lemonomycin aglycon (11) contains the typical tetracyclic core 
framework. The substitution pattern of the quinone moiety equals the one of 
naphthyridinomycin. One of the four core rings, a pyrrolidine, is new to this pool 
of alkaloids. Additional remarkable structural features are the unusually stable 
geminal diol at C16 and the 2,6-dideoxo-4-aminosugar (12) (Figure 7). This 
moiety at C18 is unique in this class of alkaloids and very scarce in nature as it 
only serves glycothiohexide α,22-24 nocathiacin I,25 and MJ347-81F4 A26 as 
substituent. It was given the name lemonose by Stoltz et al., as they were the first 
ones to synthesize the alkaloid as well as the pyranose27 and lemonomycin was 
the first natural product known to bear this structure. The sugar moiety seems to 
have an important effect on the biotic activity of these compounds, as all of them 
show similar antibiotic behavior.28 The research group around He also reported a 
derivatization of the natural compound to the corresponding cyano compound 
(14) via the intermediary formation of an iminium ion acetal (13), upon treatment 
with acidic i-propanol, to which was finally added sodium cyanide (Scheme 1).21 
 
 
Scheme 1. Conversion of Lemonomycin to the Corresponding Nitrile 
 
Biological Activity 
 
Naphthyridinomycin has shown strong activity against both Gram-positive 
and Gram-negative bacteria. It was observed, that at low concentration the 
natural product irreversibly inhibited DNA synthesis in Escherichia coli by 
avoiding the incorporation of 14C-thymidine; whereas at higher concentrations 
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RNA and protein synthesis were inhibited. Several derivatives and their biological 
activity were under intense investigation; therefore, 3H-naphthyridinomycin was 
proved to partially form covalent bonds to DNA, and the reduction of the quinone 
moiety by dithiothreitol DNA bindings occur irreversibly and at a by far higher 
extent. Strong indication exists, that naphthyridinomycin binds to GC-rich DNA 
sequences, as alkylation by poly(dG)-poly(dC) and poly(dA)-poly(dT) 
polydeoxyribonucleic acids no longer affected the DNA, as guanine was replaced 
by inosine. 
 
Bioxalomycin α2 (15), unlike naphthyridinomycin and cyanocylcline A - 
whose biological activities are almost the same - bears significantly higher activity 
against Gram-positive bacteria, due to double alkylation of the N2 of guanine in 
duplex DNA. It has been proposed, that the interaction mechanism proceeds via 
o-quinone methide intermediate 16 and subsequent oxidation of the bis-DNA 
product to the corresponding quinone 17 (Scheme 2).  
 
 
Scheme 2. DNA Interaction of Bioxalomycin α2 
 
Bioxalomycin α2 (15) is effective by a much higher extent than any other 
tetrahydroisoquinoline antibiotic, thought to arise from its two oxazolidine 
moieties and the redox-labile hydroquinone ring. Just like its congeners 
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quinocarcin and tetrazomine it shows the ability to convert oxygen into its 
superoxide.2 
 
Lemonomycin was found to have antimicrobial activity against strains of 
Staphylococcus aureus and Bacillus subtilis with MIC’s of 0.4 respectively 0.2 
μg/mL. The antibiotic was administered either orally or subcutaneously to mice, 
showing resistance to above mentioned bacteria but unfortunately at amounts 
slightly above the therapeutic dose the medication ended lethal for the test 
animal.20 Furthermore, antibiotic activity of lemonomycin (1) and its cyano-
derivative 14 against methicillin resistant Staphylococcus aureus and vancomycin 
resistant Enterococcus faecium with MIC’s of 0.4 and 0.2 μg/mL, as well as in 
vitro cytotoxicity against a human colon cell tumor line (HCT116), with IC50’s at 
0.36 and 0.26 μg/mL, were reported by He et al.21 
As lemonomycin and saframycin A (18) show similar structural 
composition, they probably obey similar biological interaction mechanisms. In 
Figure 8 the results of extensive studies on the toxicity of saframycin are 
visualized. Under mild acidic conditions (pH 5 to 6) hydrogen bonds are 
established between the minor groove of DNA. Due to calculations of the 
interplay between the natural product and the DNA duplex oligomer 
d(GATGCATC)2, indicating, that the proton of the ammonium atom N12 forms a 
hydrogen bond with the corresponding nitrogen N2 of adenine and the oxygen of 
the quinone moiety at C8 forms another one with the amine of a guanine.28 
 
 
Figure 8. DNA Interaction of Saframycin A28 
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Biosynthesis 
 
Due to their similar structural features, tetrahydroisoquinoline antitumor 
antibiotics are said to be derived by related biosynthetic pathways with amino 
acids as major building blocks. The biosynthesis leading to saframycin has been 
confirmed by isotope labeling experiments, where two tyrosine units condense to 
build the piperazine moiety and the quinone ring.29,30 Based on these studies a 
biosynthetic proposal for lemonomycin has been published in a PhD-thesis at 
California Institute of Technology (Scheme 3).28 Claiming that the piperazin 
moiety as well as the quinone ring are installed by condensation of tyrosine (19) 
with ornithine (20). 
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Scheme 3. Proposed Biosynthesis of Lemonomycin 
 
Aldehyde 22 should be derived by oxidation of the primary amine of 
diketopiperazine 21. Subsequently, elimination of water and enolization leads to 
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intermediate 23, which consecutively undergoes cyclization via intramolecular 
nucleophilic attack of an enol at its electrophile carbon atom, is claimed to furnish 
24. Glycine (25) is proposed to deliver the missing carbon atom of the 
tetrahydroisoquinoline 26; consecutive oxidation, hydrolysis and reduction should 
arise in primary alcohol 27, bearing the tetracyclic carbon core with all five 
stereogenic centers set correctly. Finally, oxidation of the aromatic ring to the 
corresponding quinone 28, methylation via the S-methyl methionine and 
glycosylation with lemonose (12) should provide (-)-lemonomycin (1). 
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PRELIMINARY SYNTHETIC EFFORTS 
 
The Total Synthesis of Lemonomycin 
 
Today, only one total synthesis of (-)-lemonomycin has been published by 
Stoltz et al. in 2003,27 59 years after its isolation. Starting from cheap and readily 
available material, the desired natural product was obtained in 15 linear steps. 
According to their retrosynthetic consideration the key steps of the synthetic route 
are a diastereoselective dipolar Joule reaction to lead to diazabicycle 31, a 
Suzuki cross coupling between iodide 32 and boronic ester 33 as well as a 
diastereoselective Pictet-Spengler cyclization of intermediate 36 and the 
α-glycosylated dideoxysugar 31. The aminopyranose itself was obtained starting 
from D-threonine by Felkin-controlled aldol reaction as crucial step. 
 
Diazabicyclo iodide 32 could be obtained in four steps. Therefore, 
deprotonation of oxidopyrazinium bromide 29 with N-methyl morpholine as base 
and treatment with Oppolzer sultam-derived acrylamide 30 provided a bicyclic 
product, which under reduction conditions with sodium borohydride gave primary 
alcohol 31 in high yield (72%) and an excellent enantiomeric excess of 94%. 
Protection of the alcohol as a silyl ether and iodination gave Z-iodoenamine as a 
single diastereomer. The arising iodide 32 was linked to boronester 33 via Suzuki 
coupling giving enamide 34. Hydrogenation of the Z-double bond with palladium 
on charcoal was accompanied by cleavage of the nitrogen linked benzyl group 
providing an amide. Subsequently, the secondary amine was protected as benzyl 
carbamate and the sulfonate ester was cleaved, obtaining amide 35. Stoltz et al. 
were not able to perform a Pictet-Spengler cyclization at this stage of the 
synthesis, as the reactivity of the amide towards aminoglycosyloxy aldehyde 41 
was not existent. The more reactive primary amine 36 was established by 
activation of the secondary amine as t-butyl carbamate (the phenol was also 
affected), followed by reductive opening of the piperazine ring and acidic 
cleavage of both prior installed Boc groups and the silyl ether (Scheme 4). 
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Scheme 4. Synthesis of the Pictet-Spengler Precursor 
 
The aminoglycosyloxy aldehyde itself was provided by conversion of 
D-threonine (Scheme 5). As the only diastereomer, Felkin-controlled aldol 
product 38 was derived by alkylation of ketone 37 with the in situ prepared lithium 
enolate of ethyl acetate. Acidic opening of the oxazolidine with concomitant 
formation of a lactone, formation of an oxazolidine, reduction of the prior installed 
lactone to the lactol and its conversion with allyl alcohol provided bicycle 39. 
Later, the oxazolidine together with the sulfonyl group was reductively cleaved 
and the arising secondary amine was methylated. Finally, to obtain the desired 
aminopyranose, 41 was derived by glycol cleavage performed with osmium 
tetroxide in the presence of sodium periodate. 
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Scheme 5. Synthesis of the Sugar Moiety 
 
Pictet-Spengler reaction of amino alcohol 36 as corresponding TFA salt 
with aldehyde 41 was diastereoselectively performed by simply mixing both 
substances in EtOH at room temperature (Scheme 6). 
 
 
Scheme 6. Endgame of the Total Synthesis 
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To complete the total synthesis, what was left to do with tetrahydroisoquinoline 
42, was the hydrogenative cleavage of the nitrogen protecting group, Swern 
oxidation of the primary alcohol followed by immediate closure of the piperazine 
ring and oxidation of the aromatic ring to provide the natural compound 1. 
 
 
Synthetic Contributions Towards a Total Synthesis of 
Lemonomycin 
 
This section will give a comprehensive chronological overview of synthetic 
studies and syntheses of lemonomycin derivatives. 
Within the last decade several noteworthy achievements toward syntheses of 
lemonomycin have been published by various research groups. 
 
Magnus’ Racemic Synthesis of Advanced Lemonomycinone Amide 
 
In 2005, Magnus et al. reported a racemic synthesis of lemonomycin 
amide 60 and the racemic total synthesis of another tetrahydroisoquinoline 
alkaloid renieramycin G from a common intermediate, starting from cheap and 
readily available material.31 The lemonomycin derivative shows all crucial 
structural features of the natural compound’s aglycon, except that the 
carbinolamine functionality is present as lactam. Key steps of this synthetic 
approach are a modified Larock synthesis providing isoquinoline 45, a silyl 
activated amide coupling reaction and a thiophile mediated N-acyliminium 
cyclization giving aldehyde 57. 
Linkage of benzylic o-iodoimine 43 with triisopropylsilyl protected 
propargylic alcohol 44 by modified Larock isoquinoline synthesis and subsequent 
copper mediated ring closure under Castro’s conditions gave electronrich 
isoquinoline 45. Alkylation of the resulting bicycle with benzyloxymethyl lithium 
and consecutive treatment with methyl chloroformate gave cyclic tertiary enamine 
46. As direct reduction to intermediate 48 worked unsatisfactory due to 
degradation of the isoquinoline, the amino alcohol was obtained by conversion of 
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the silyl ether to oxazolidinone 47, using TBAF, followed by ionic hydrogenation 
and hydrazinolysis. Subsequently, treatment with TMSCl leading to protection of 
the primary alcohol and concomitant activation of the amine, and its coupling with 
mixed anhydride 49 provided cyclization precursor 50 after acidic workup. The 
following Swern oxidation was accompanied by direct formation of the piperazine 
ring resulting in a diastereomeric (3:2) mixture of hemiaminal 51. The common 
intermediate 52 on the synthetic routes to renieramycin G and lemonomycin 
could be generated by substrate controlled diastereospecific conversion to its 
thioaminal (Scheme 7). 
 
 
Scheme 7. Route to the Magnus Thioaminal 
 
Following the pathway towards lemonomycin, amide 52 was alkylated with 
iodide 53 giving the single undesired diastereomer 54, which was fully converted 
to the desired one by deprotonation with t-BuLi and quenching with BHT. 
Removal of the silylether under standard conditions gave alcohol 55. The silyl 
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enolether 56 was established by Swern oxidation and consecutive treatment with 
TIPS-triflate. The crucial diastereoselective N-acyliminium cyclization was 
performed in the presence of thiophilic AgBF4 providing intermediate 57 bearing 
the tetracyclic carbon framework of the natural compound. 
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Scheme 8. Endgame to Magnus’ Racemic Lemonomycinone Amide 
 
Hydrogenolysis of both present benzyl protection groups gave compound 
58, whose aldehyde functionality was transformed into the unusual hydrate 
moiety concomitant to the cleavage of the carbamate yielding amine 59 as 
hydrochloride salt. To complete the endgame of this racemic synthesis, what was 
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left to do was the oxidation of the hydroquinone to its corresponding quinone 60 
with CAN (Scheme 8). 
Magnus et al. managed to synthesize racemic lemonomycin in 19 steps 
and an overall yield of 5% starting from imine 43. 
 
Fukuyama’s Sterocontrolled Synthesis of the Carbon Skeleton of 
(‐)‐Lemonomycin 
 
Fukuyama et al. reported a stereocontrolled synthesis of the 
3,8-diazabicyclo[3.2.1]octane skeleton of (-)-lemonomycin in 2004.32 An Ugi 
reaction using amino acids, a N-acyliminium cyclization to form the pyrrolidine 
moiety and a cross metathesis using 2nd generation Grubbs catalyst were the key 
steps in their synthesis of advanced precursor 71 of the natural compound. 
The Ugi reaction of isocyanide 64, dimethyl carbonate 63, amino acid 62 
and benzylic amine 61 in trifluoroethanol established diamido acetal 65. Closure 
of the piperazine ring with CSA and consecutive formation of an oxazolidinone 
with potassium t-butanol provided intermediate 66. N-Acyliminium cyclization 
precursor 68 was derived by reductive cleavage of the oxazolidinone, acetylation 
of the arising alcohol, concomitant deprotection and reprotection of the former 
silyl ether as acetate and final cross metathesis with allyltrimethylsilane (67). The 
following cyclization by cleavage of the carbon-silicon bond was carried out with 
boron trifluoride etherate as Lewis acid providing tricycle 69. A protection 
reprotection sequence, affecting the Boc protected amine and the acetate, 
followed by a DMDO oxidation gave hemiaminal ether 70. Finally, acyliminium 
mediated reduction, occurring from the less hindered exo-face, change of the 
phenol protecting group, Dess-Martin oxidation and TFA mediated cyclization 
gave amide 71, completing the synthetic studies of Fukuyama and coworkers. 
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Scheme 9. Fukuyama’s Contribution 
 
This stereocontrolled synthesis of an advanced precursor of lemonomycin 
was preformed in 16 steps and an overall yield of 5% from readily available 
starting materials. 
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Zhu’s First Synthetic Efforts Towards a Total Synthesis of Lemonomycin 
 
Two years later, in 2006, pursuing the total synthesis of (-)-lemonomycin, 
after they finished a total synthesis of the congener ecteinascidine 743, J. Zhu 
and coworkers reported the synthesis of an advanced tricyclic intermediate of 1.33 
The first key step of this approach, the enantioselective alkylation of 
N-(diphenylmethylene)glycine t-butyl ester 73, with literature known benzylic 
bromide 72, in the use of O-(9)-allyl-N-(9’-anthracenylmethyl) cinchonidium 
bromide 74 provided tyrosine related ester 75 with an ee of higher than 90%. 
Subsequently, protection of the primary amine as carbamate, saponification of 
the ester under mild acidic conditions and coupling with 2,2-dimethoxy ethanol 
(76) gave cyclization precursor 77. After oxidation of the acetal to the 
corresponding aldehyde, intramolecular Pictet-Spengler cyclization, consecutive 
cleavage of the benzylcarbamate and change of silyl ether protection group to 
benzyl, lactone-bridged tetrahydroisoquinoline 78 was obtained. In two more 
steps lactol 80 was afforded, by coupling of the isoquinoline with L-5,5’-dimethyl-
N-Cbz-4-carboxy-glutamate (79) and subsequent chemoselective reduction of the 
lactone. 
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Scheme 10. Synthesis of Zhu’s Lactol Bridged Intermediate 
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Piperazine derivative 81 was derived under Lewis acidic conditions as 
iminium ion intermediate. Unluckily, the desired intramolecular nucleophilic 
addition onto the present electrophilic center was not successful, thus the initially 
desired tetracyclic compound 82 could not be isolated. Iminium ion 81, finally 
shifted the double bond, via its enamine tautomer, into the favored conjugated 
position, providing product 83. Exposure to Krapcho conditions, concomitant 
reduction of the ester and amide functionalities and consecutive cyclization of the 
free alcohol onto the carbinol moiety gave an unstable amine 84, which finally 
turned into enamine 85 upon impact of air-oxygen. 
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Scheme 11. Zhu’s Endgame Towards the Enamine Intermediate 
 
William’s Synthesis of an Advanced Intermediate of Lemonomycin 
 
Williams et al. synthetic efforts towards lemonomycin, based on a 
[1,3]-dipolar cycloaddition and an intramolecular condensation reaction, were 
published in 2007.34 
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Tetrahydroisoquinoline 88 was derived from iodide 86 and compound 87, 
achieved from glycine, as main building blocks. After the coupling, protection 
group manipulation, concomitant partial cleavage of the auxiliary, reductive 
treatment of mixed anhydride intermediate and consecutive Pictet-Spenlger 
cyclization with ethylglyoxylate afforded the tetrahydroisoquinoline intermediate 
88 as a single diastereomer. Subsequently, the free phenol was acetylated, the 
auxiliary was cleaved off and the freed secondary amine was subject of coupling 
with 2-(benzyl(Boc)amino)acetic acid (89). Amino aldehyde 90, as precursor for 
the closure of the piperazine ring, was obtained after removal of the silyl 
protecting group and consecutive Swern oxidation. Cleavage of the Boc 
protecting group led to the desired ring closure providing an iminium ion 91, 
which, similar to Zhu’s former approach33 (vide supra), tautomerized to the 
favored conjugated olefin 92. Consecutive TEMPO oxidation gave iminium ion 
93, which underwent [1,3]-dipolar cycloaddition under treatment with 
triethylamine and tert-butyl acrylate forming tetracyclic compound 94 via an initial 
azomethine ylide. 
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Scheme 12. Williams’ Contribution 
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The configuration of the benzylic stereogenic center is the opposite as in 
the natural product, the hemiaminal moiety is present as an amide and the 
achieved advanced intermediate bears an undesired double bond in the 
isoquinoline core fragment. 
 
Mulzer et al. were the next scientist to contribute a report containing 
synthetic efforts towards an advanced precursor of lemonomycin in 2008.35 This 
publication will be discussed later on in the Results and Discussion section, as it 
will directly lead to our recent work. 
 
Zhu’s Second Contribution; Synthesis of an Advanced Lemonomycinone 
Amide 
 
The most recently published report of the synthesis of an lemonomycin-
aglycon derivative was edited by Zhu and coworkers.36 The synthesis of 
lemonomycinone amide (107) started from a common point of their former 
publication, even with the tyrosine related intermediate 75, derived by 
enantioselective alkylation as already mentioned (vide supra).33 Cleavage of the 
silyl ether and consecutive diastereoselective Pictet-Spengler cyclization with 
benzyloxy acetaldehyde (99) gave tetrahydroisoquinoline 100. Subsequently, 
protection of the free phenol and the secondary amine and consecutive 
transesterification of the t-butyl ester to the corresponding methyl ester provided 
suitable intermediate 101 for the peptide coupling with amino acid 98. 
The amino acid itself was obtained in seven steps starting with L-glutamic acid 95 
as described in Scheme 13.  
 
23 | P a g e  
 
HO2C
CO2H
NH2
95
MeO2C
CO2Me
NHBoc
96
MeO2C
NBoc2
97
HO2C
NHBoc
98 OHOTBS
1. TMSCl, MeOH
2. Boc2O, NEt3
95%
1. Boc2O, DMAP
2. DIBALH
then NaBH4
84%
1. CeCl3.7H2O, NaI
2. TBSCl, imidazole
3. LiOH, THF/H2O
76%  
 
Scheme 13. Zhu’s Side Chain 
 
The linear synthesis was further prosecuted by reduction of the ester 
functionality of 102, oxidation of the newly formed alcohol to the aldehyde, which 
cyclized upon cleavage of the carbamate protection group affording tricyclic 
intermediate 103 as a mixture of diastereomers.  
 
 
Scheme 14. Zhu’s Second Approach towards an Advanced Intermediate of Lemonomycin 
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Treatment of the mixture of diastereomers with EtSH, as noted in Scheme 
14, and concomitant cleavage of the TBS group provided thioaminal 104 as 
single diastereomer. Intramolecular Mannich reaction, promoted by silver 
tetrafluoroborate, of 105 was carried out after conversion of the free alcohol to 
TIPS trapped enol. Hydrogenolysis of the benzyl protecting group, cleavage of 
the Boc group with accompanied hydration of the aldehyde functionality and 
oxidation of the aromatic system to the corresponding quinone, converted 106 
into the desired amide. The product 107, with all stereogenic centers in the 
carbon core framework set correctly, was derived with an overall yield of 12% 
starting form cheap 2,6-dimethoxytoluene. 
 
Short Summary of Synthetic Approaches 
 
As outlined in this section only one total synthesis of (-)-lemonomycin is 
known to this very date. This enantioselective synthesis was published in 2003, 
although the natural compound was isolated in 1964 and its structure was 
elucidated in 2000. The enantioselective total synthesis of this 
tetrahydroisoquinoline antitumor antibiotic was performed with an overall yield of 
3%. Among to date known seven synthetic efforts towards lemonomycin, it is the 
only approach not starting from an aromatic moiety, which later on is converted 
into a quinone, but with a piperazine precursor; and with the longest linear 
sequence of 15 steps it is definitely straight forward. 
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RESULTS AND DISCUSSION 
 
Preliminary Synthetic Efforts and the Arising Strategy 
 
In 2008 Mulzer and coworkers, published their stereocontrolled synthesis of the 
tetracyclic core frame work of (-)-lemonomycin (1).35 
According to extensively investigated options to synthesize cyanocycline A 
(115), which shows a partially similar carbon core, we based our retrosynthetic 
analysis on former studies on this natural product. As outlined in Scheme 15, 
both synthetic approaches have advanced key intermediate 112 in common, with 
rings B, C and D already closed.  
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Scheme 15. Retrosynthetic Analysis of Lemonomycin and Cyanocycline A 
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Installation of the labile quinone and unusual hydrate moiety, as well as 
the glycosylation with the amino sugar was thought to be elaborated at a later 
stage of the synthesis. Linkage of readily available starting materials, 108 and 
109, Pictet-Spengler cyclization to install ring C, a Strecker-like reaction of 
cyanohydrin side chain 111 and tetrahydroisoquinoline 110 and finally a 
N-acyliminium cyclization to form the pyrrolidine ring were thought to be the key 
steps, leading towards lemonomycin. The synthetic efforts towards a total 
synthesis of cyanocycline A will not be discussed in further detail.37 
 
In 2008, Mulzer et al. published the synthesis of advanced 
lemonomycinone nitrile 121, starting with the alkylation of Fmoc protected 
Garner’s aldehyde 109 with bromide 108, providing 116, favoring the desired 
diastereomer at a ratio of 5:2. Within an oxidation reduction sequence the mixture 
of diastereomer was converted into the syn product using PCC and DIBALH, and 
subsequently the alcohol was protected as silyl ether. The oxazolidine 
intermediate 117 was opened concomitant to the cleavage of the carbamate 
protection group. The arising primary alcohol was protected with TESCl and the 
benzyl group linked to the phenol was cleaved by hydrogenation, providing 
cyclization precursor 118.  
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Scheme 16. Mulzer’s Synthesis of the Tetrahydroisoquinoline Intermediate 
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The Pictet-Spengler reaction with benzyloxy acetaldehyde (99) was 
elaborated by the use of a catalytic amount of acetic acid and crushed 4 Å 
molecular sieves. Tetrahydroisoquinoline 110 was obtained as a single 
diastereomer in high yield. The cyanohydrine side chain 102 was provided by 
cross metathesis of allytrimethylsilane and allylbromide followed by Myers’ 
enantioselective alkylation reaction and four consecutive literature known 
steps.38,39 
The linkage of tetrahydroisoquinoline 110 and side chain 111 was 
performed with 2,2,2-trifluoroethanol in high yield. Acetylation of the phenol, 
selective cleavage of the TES group and consecutive oxidation with Dess-Martin 
periodinane directly afforded tricyclic substrate 120 bearing the piperazine 
moiety. Treatment with TFA provided tetracyclic lemonomycin precursor 121 at 
moderate yield. 
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Scheme 17. Mulzer’s Endgame Towards Lemonomycinone Nitrile 
 
According to the proposed cascade reaction mechanism the configuration 
of the nitrile linked stereogenic center at C17 was inverted, forming the less bulky 
equatorial isomer, subsequent to the iminium ion 122 mediated formation of the 
pyrrolidine ring. 
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Scheme 18. Mechanistic Proposal for the Cyclization and the Inversion of the Stereogenic Center 
 
Based on this 13 steps lasting approach towards lemonomycin derivative 
121, we developed a new, slightly modified approach. Removal of the benzylic 
hydroxyl group, arising from the alkylation of Garner’s Aldehyde with bromide 
108, should shorten the synthesis by at least one reaction step. 
 
 
Main Building Blocks 
 
The Aromatic Portion 
 
According to previous synthetic efforts, aromatic bromide 108 was thought 
to be a suitable building block for the alkylation of Garner’s aldehyde (109, 134). 
Bromide 108 was synthesized from cheap and readily available 
2,6-dimethoxytoluene (126).40,41 Friedel-Crafts acylation and consecutive Bayer-
Villiger oxidation with mCPBA provided acetate 127. After saponification of the 
ester functionality and protection of the freed phenol intermediate 128 was 
obtained. Finally, selective bromination of the para, respectively the ortho position 
of both methoxy groups, afforded desired precursor 108. This five steps lasting 
reaction sequence was pursued with an overall yield of 50%. The restricting step 
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was the Bayer-Villiger oxidation as it was performed with a maximum yield of 
69%. 
 
 
Scheme 19. Synthesis of the Aromatic Building Block 
 
Garner’s Aldehyde 
 
Commercially available Garner’s aldehyde was synthesized from L-serine 
in two modifications, either Cbz or Fmoc protected.42,43 Therefore, the chirality of 
the later building block was introduced by the starting material itself. 
 
 
Scheme 20. Synthesis of Garner’s Aldehydes 
 
In the first step, the non essential amino acid L-serine (129) was converted into 
its corresponding methyl ester, which was isolated as hydrochloride salt and 
respectively protected either as benzyl- or 9-fluorenylmethyl carbamate, providing 
compound 130 and 131. Formation of an amino acetal with 
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2,2-dimethoxypropane under Lewis acidic conditions afforded oxazolidine 132, 
respectively 133. Reduction of the ester functionality and consecutive oxidation of 
the prior installed alcohol gave desired compounds 134 and 109.44 
 
Alkylation Reaction 
 
With both major building blocks in hands the planned alkylation reaction 
could be performed. Therefore, aromatic bromide 108 was treated with n-BuLi at 
-78 °C, to in situ form the lithium species, which then alkylated Garner’s 
aldehydes (109, 134). As the yield and diastereomeric ratio of this reaction 
varied, some optimization work had to be done at this stage of the reaction 
sequence (Scheme 21, Table 1). 
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Scheme 21. The Alkylation of Garner’s Aldehyde 
 
Changing the solvent from THF to toluene dramatically improved the yield 
of this reaction. From the reactions in THF, besides the desired product, bromide 
108 was isolated as its corresponding alcohol, indicating, that the lithiation of the 
halide took place, but by some reason, which was not investigated, the alkylation 
of Garner’s aldehyde was unsuccessful. 
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Reaction No. R1 R2 PG Conditions d.e. Yield 
1 Br Bn Cbz THF, n-BuLi, -78 °C 2.3 : 1 23 - 75% 
2 Br Bn Fmoc THF, n-BuLi, -78 °C 2.1 : 1 20% 
3 Br Bn Fmoc THF, t-BuLi, -78 °C X X 
4 Br Bn Cbz THF, t-BuLi, -78 °C X X 
5 Br Bn Fmoc toluene, n-BuLi, -78 °C 1.8 : 1 54% 
6 Br Bn Cbz toluene, n-BuLi, -78 °C 2.7 : 1 96% 
7 H TIPS Fmoc THF, MeMgCl, r.t. then 0 °C 2.3 : 1 71% 
 
Table 1. Conditions for the Alkylation of Garner’s Aldehyde 
 
Parallel to this effort a second aromatic portion 137, derived from vanillin 
(139) (Scheme 22), was prepared,45 which should have been a suitable 
alternative for the alkylation of 109 (reaction No. 7 in Table 1), if we would not 
have been able to solve this problem. 
 
 
Scheme 22. Synthesis of the Alternative Aromate 
 
Improving the Diastereomeric Ratio 
 
The next goal was to optimize the stereochemical control of this synthesis. 
Therefore, the most obvious opportunity was to dehydroxylate the benzylic 
position via hydrogenolysis in a Parr-hydrogenation apparatus. Under these 
conditions the benzylic hydroxyl functionality was not affected at all, but the 
oxazolidine was opened and - only to a small amount - the benzyl group was 
cleaved. Different conditions by the use of TMSCl and sodium iodide, were 
uneffective, resulting in decomposition of the starting material. Desired 
dehydroxylated product 147 was obtained by the use of the Barton-McCombie 
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reaction via the radical substitution with tributyltin hydride of the prior formed 
xanthate 146. 
As dehydroxylation with triethylsilane and TFA was accompanied by the 
cleavage of the oxazolidine moiety and the reaction could be elaborated in much 
higher yield, it was regarded as the method of choice.  
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Scheme 23. Strategies to Remove the Benzylic Hydroxy Functionality 
 
At this stage of the synthesis, we were not sure if removal of the 
stereogenic center in the benzylic position would affect the diastereoselectivity of 
the planed cyclization, nonetheless we decided to pursue this strategy. 
After some protection group operations, product 144, respectively 145, 
should have provided the desired Pictet-Spengler cyclization precursor, but as 
mentioned in the next section, these steps bared some unexpected problems. 
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The Benzylic Problem 
 
To perform the Pictet-Spengler reaction, a free phenol group ortho to the 
unsubstituted phenol position was needed. First, cleavage of the benzyl group of 
145 with standard hydrogenation conditions was elaborated, which in the former 
contribution by Mulzer35 was performed successfully. This deprotection would 
provide a secondary amino alcohol with a free phenol. But as outlined in Table 2, 
aminophenol 145 was not affected and the starting material could be recovered 
almost quantitatively. 
Therefore, another intermediate (149), with a free amine and an alcohol 
protected as a silyl ether, was tested to investigate if the failure of the prior 
attempts to cleave the benzyl group was substrate related. But these reactions 
also failed, as the starting material remained unaffected. The substrates and 
solvents were inspected for impurities and, if necessary, purified or changed, 
unfortunately not leading to any result at that time. 
The next modification of the starting material, as its amino functionality 
was left as carbamate and the alcohol in the α-position was protected as silyl 
ether, was expected to deliver better results. Surprisingly, hydrogenation with 
palladium on charcoal catalyst did not result in the desired deprotected phenol 
151, but the less reactive Lindlar catalyst led to Pictet-Spengler precursor 145 in 
low yield. With palladium hydroxide better results were obtained, as the benzyl 
group was cleaved. But probably due to the in situ formation of HCl from residual 
chloride impurities - present in the reagent because of its preparation procedure –
lowered the yield to 50%, as the TES group was partially cleaved. As the last 
experiment indicated, hydrogenative deprotection definitely was possible and to 
avoid cleavage of the silyl ether, more active palladium on charcoal under much 
higher hydrogen pressure of 70 bar was suggested to be suitable conditions, but 
again the starting material was not affected. 
In substrate 150 two aromatic rings were present, the benzyl group and 
the more electron rich and highly substituted one. Lithium was chosen to be the 
suitable alkali metal for the reductive cleavage of the aromatic protecting group 
under Birch conditions, as it is less reactive than sodium and therefore it should 
leave the electron rich aromatic ring unaffected. The reaction was performed in a 
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maximum yield of 31% providing free phenol 153. As no other product was 
isolated and unaffected starting material was recovered this method was 
performed in a cyclic way and was favored in regard to the hydrogenation 
reaction. 
 
 
 
Scheme 24. Elaboration of the Prictet-Spengler Cyclization Precursor 
 
Reaction No. R1 R2 Conditions Yield 
1 H Fmoc H2, Pd/C (5 w%), EA X 
2 H Fmoc H2, Pd/C (5 w%), EA, 3 bar X 
3 H Fmoc H2, Pd/C (5 w%), AcOH, MeOH : EA (3 : 2) X 
4 TES H H2, Pd/C (5 w%), MeOH X 
5 TES H H2, Pd/C (5 w%), MeOH 3 bar X 
6 TES Fmoc H2, Pd/C (5 w%), MeOH : EA X 
7 TES Fmoc H2, Pd/CaCO3 (10 w%), EA, 3 bar 14% 
8 TES Fmoc H2, Pd(OH)2/C (20 w%), MeOH : EA (3 : 2), 3 bar 50% 
9 TES Fmoc H2, Pd/C (5 w%), MeOH : EA (3 : 2), 70 bar X 
10 TBS H Li, NH3 (l.), THF : t-BuOH (3 : 2), -78 °C 31% 
 
Table 2. Conditions for the Benzyl Group Cleavage 
 
Cleavage of the carbamate protecting group was carried out under 
standard conditions providing cyclization precursor 146. The Pictet-Spengler 
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reaction could not be elaborated at his stage of the synthesis, as the amount of 
obtained cyclization precursor was too small to allow a reproducible reaction 
procedure. 
The dramatical change of reactivity of the benzyl group by modification of 
the former tetrahydroisoquinoline approach (vide supra), wherein the protection 
group was cleaved by hydrogenation with palladium on charcoal under normal 
pressure and high yield, was the driving force to investigate other synthetic 
strategies to obtain a tetrahydroisoquinoline intermediate of lemonomycin. 
 
 
Alternative Approaches Towards the Tetrahydroisoquinoline Key 
Intermediate 
 
With the aim to improve the efficiency of the former approach, alternative 
strategies to provide a suitable tetrahydroisoquinoline for the endgame towards 
aglycon nitrile 158 were elaborated and the following slightly modified 
retrosynthetic analysis was proposed. 
 
 
 
Scheme 25. The Alternative Retrosynthetic Strategy Towards Lemonomycinone Aglycon Nitrile 
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Benzylic bromide 156 was obtained according to Scheme 26. Halide metal 
exchange and consecutive alkylation of DMF afforded the desired benzaldehyde 
155 for the HWE approach. Finally, reductive treatment with sodium borohydride 
and conversion of the obtained benzylic alcohol into the corresponding bromide 
via Appel reaction provided desired building block 156. 
 
 
 
Scheme 26. Synthesis of the Benzylic Aldehyde and Bromide 
 
Aza‐lactonization Approach 
 
Similar to the literature known formation of α-acetaminocinnamic acid,46 
compound 161 could be established via an aza-lactonization with acetylglycine 
(151) and subsequent hydrolysis. Therefore, a solution of benzaldehyde 147, 
acetyl glycine 151 and sodium acetate in acetic anhydride was heated to 140 °C 
in a sealed tube. Unfortunately aza-lactone 152 could not be derived and this 
approach was abandoned. 
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Scheme 27. The Aza-lactonization Approach 
 
The next steps would have been esterification of the amido acid and 
subsequent reduction to the corresponding alcohol. Protection of the alcohol as 
silyl ether followed by asymmetric hydrogenation47 of the enamino silylether and 
concomitant cleavage of the benzyl group should have provided a suitable 
precursor for the Pictet-Spengler cyclization. 
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Horner‐Wadsworth‐Emmons Approach 
 
According to preliminary retrosynthetic considerations, Horner-Wadsworth-
Emmons olefination of benzaldehyde 155 and phosphonate 165 should 
selectively provide desired E-alken 166 in regard to the carbon substituents of the 
formed double bond. 
Initially, phosphonate 165 was derived from glyoxalic acid (155) and 
benzylcarbamate (154) by condensation, ester- and etherification and 
subsequent conversion into phosphonate 165 as outlined in Scheme 28. 
Subsequently, the olefination reaction was carried out with DBU providing 
enamine 166 as a single diastereomer. 
 
 
 
Scheme 28. The Horner-Wadsworth-Emmons Approach 
 
As one of the contemporaneously elaborated alkylation reactions was 
delivering good results we decided not to pursue further reactions, which would 
have been enantioselective hydrogenation47 and concomitant or subsequent 
removal of the benzyl group, leading to a suitable cyclization precursor. 
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Myers’ Alkylation Approach 
 
Commercially available (-)-pseudoephedrine glycine amide 167, bearing 
the chiral auxiliary and therefore controlling the enantioselectivity of this reaction, 
was alkylated with bromide 156, providing secondary α-amino amide 168. 
Consecutive reductive cleavage of the auxiliary afforded amino alcohol 169. Due 
to the unsatisfying yield of this reaction and a recent progress with a heterogenic 
catalyzed alkylation reaction (vide infra), the Myers’ alkylation approach was 
abandoned. 
 
 
Scheme 29. The Myers’ Enantioselective Alkylation Approach 
 
Enantioselective Alkylation via Corey‐Lygo’s Phase Transfer Catalyst 
 
As the structure of cyclization precursor 153 is strongly related to the 
amino acid L-tyrosine, two new synthetic suggestions were investigated. The first 
option would have been to import the correct stereochemistry via the amino acid 
as starting material followed by modification of the aromatic moiety. According to 
our preliminary retrosynthetic analysis (vide infra), we decided to focus our 
synthetic efforts on the use of the enantioselective alkylation reaction by the use 
of Corey-Lygo’s cinchonidium catylst 74.48,49  
Therefore, N-diphenylmethylene glycine t-butyl ester (73)50 was treated with 
CsOH.H2O in the presence of catalyst 74. Subsequently, bromide 156, as it was 
used in the former Myers’ alkylation approach, was added at low temperature 
under vigorous stirring, which was reported to be the crucial restricting factor of 
the reaction time.51 Imine 170 was provided in excellent yield and was directly 
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hydrolyzed to the corresponding amino ester 171. The ee of 88% was determined 
by comparison of the NMR-data of elaborated S- and R-Mosher amide (184, 
186). The present t-butyl ester was reduced to the corresponding alcohol and 
protected as silyl ether. Desired Pictet-Spengler cyclization precursor 152 was 
derived via cleavage of the benzyl group under Birch conditions (vide supra). 
Finally, tetrahydroisoquinoline 173 was obtained in excellent yield by addition of 
benzyloxy acetaldehyde 99 to a solution of amino phenol 152 under acidic 
conditions in the presence of crushed 4 Å molecular sieves as single 
diastereomer. 
 
 
 
Scheme 30. The Enantioselective Alkylation Approach via Corey-Lygo Cinchonidium Catalyst 
 
Zhu and coworkers already adopted Corey-Lygo’s phase transfer catalyst 
in their total synthesis of quinocarcin and in their synthetic studies towards 
lemonomycin in 2006 (vide supra).33 
 
As the benzyl group was not the most convenient protection group in this 
synthesis, it was redesigned for MOM protected analog 168 of benzylic bromide 
148 (vide infra). Detailed experimental procedures leading to this aromatic 
building block will be presented in a later section. Again enantioselective 
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alkylation was used to install the crucial stereocenter in α-position to the ester 
functionality. Reduction of the ester and protection of the prior installed alcohol as 
silyl ether provided compound 176.  
 
 
Scheme 31. The Promising Approach with the MOM Analog 
 
Cleavage of the methoxymethyl moiety and consecutive Pictet-Spengler 
cyclization of compound 171 could not be elaborated at this stage of the 
synthesis, but the MOM protection group will be easily cleaved by the use of 
TMSBr or under acidic conditions. 
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OUTLOOK 
 
The alternative synthetic route via the MOM protected aromate is currently topic 
of our investigation, showing equal enantioselectivity in the heterogeneous 
alkylation reaction and excellent yields in the already elaborated reaction steps. 
With tetrahydroisoquinoline 173, respectively 178 in hands, the endgame 
described in Scheme 17, which was accomplished with substrate 110,35 
possessing a similar silyl protection group, should lead us to aglycon nitrile 158. 
 
CONCLUSION 
 
The rings D and C of (-)-Lemonomycin were installed with all present 
stereogenic centers set correctly, following a synthetic route containing an 
enantioselective heterogeneously catalyzed alkylation and the classic Pictet-
Spengler reaction as key steps. Tetrahydroisoquinoline 173 was obtained in 8% 
yield and 14 linear steps starting from inexpensive 2,6-dimethoxytoluene with 
excellent enantioselectivity.  
To increase the yield the analog route with the MOM protected phenol 174, 
as the cleavage of the benzyl group was the restricting reaction step in the 
elaborated synthesis, will be subject of our future work. 
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EXPERIMENTAL SECTION 
 
General Experimental Procedures: 
 
Synthetic methods 
Reaction vessels for moisture- and air-sensitive reactions were flame dried 
with a heat gun or a Bunsen-burner under vaccum and consecutively purged with 
argon. Where needed, reactions were performed under slight over pressure of 
argon (balloon) in dry solvents. Sensitive solvents and reagents were either 
transferred by double tipped needle or syringe through rubber septa to predried 
vessels. If not mentioned otherwise, all reactions were stirred magnetically. 
 
Solvents and Reagents 
Commercial reagents were checked for impurities by NMR spectroscopy 
and thin-layer chromatography and were used as delivered unless otherwise 
noted. Freeze-pump-thaw technique was used to degas reaction mixtures and 
solvents where needed. 
Methanol, dichloromethane (DCM), N,N-dimethyl formamide (DMF), 
acetonitrile, hexane, ethyl acetate (EA), diisopropylamine (DIPA), 
diisopropylethylamin (DIPEA) and triethylamine (TEA) were distilled form calcium 
hydride. Tetrathydrofuran (THF), toluene, benzene and diethylether were refluxed 
with sodium in the presence of benzophenone and were freshly distilled prior to 
use. 
Dry solvents were stored under argon atmosphere over 4 Å molecular sieves in 
predried vessels. 
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Analytics and Purification 
 
Thin‐layer chromatography (tlc) 
Coated aluminum sheets and glass plates, both E. Merck silica gel 60-F254  
impregnated with a 254 nm fluorescent indicator, were used for reaction control. 
TLC was usually developed with either a DCM/MeOH or a hexane/EE mixtures 
mentioned in the respective procedures. UV-active spots were detected at 
longwave (254 nm) or shortwave UV (180 nm). Additionally most developed 
tlc-plates were treated with following visualization reagents followed by heating 
with a heat gun: acidic ninhydrin solution in butanol (dying amines and imines); 
aqueous ceric ammonium molybdate solution (CAM); acidic vanillin solution in 
ethanol or anisic aldehyde in acetic anhydride. 
 
Column chromatography 
Preparative flash-column-chromatography was carried out using silica gel 
(Merck KGA, 60 Å pore size, 230-240 mesh). As eluents, mixtures (detailed 
compositions are reported in the procedures) of either hexane/ethyl acetate or 
DCM/MeOH were used; in the first case “dry packing” and in the second “wet 
packing” were chosen as routine conditioning circumstance. 
 
NMR Spectroscopy 
1H NMR and 13C NMR spectra were recorded on either Bruker Avance 250 
MHz, Avance 400 MHz or Avance III 400 MHz spectrometer. Deuterated 
chloroform was chosen as the desired solvent for all measurements, also serving 
as internal reverence with its respective residual signals (1H, δ = 7.26; 13C, 
δ = 77.0). 
Chemical shifts of proton and carbon resonances are given in parts per million 
(ppm, δ scale) referring to the resonance of trimethylsilane. Coupling constants J 
are reported in Hz (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
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br = broad signal). Assignment of proton resonances was, as far as possible, 
confirmed by 2D spectra (COSY, HSQC, HMQC, NOESY). 
 
Mass Spectroscopy 
Mass spectra were measured on Micro Mass, Fissions Instrument and 
Trio200 spectrometers. HRMS were taken with a Finnigan MAT 8230 with a 
resolution of 10000. 
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Experimental Procedures 
 
1‐(2,4‐Dimethoxy‐3‐methylphenyl)ethanone (179) 
 
A round-bottomed flask equipped with a reflux condenser was charged 
with titanium tetrachloride (86.45 mL, 788 mmol, 2 equiv.) and cooled to 0 °C. 
Upon the drop wise addition of acetyl chloride (56.01 mL, 788 mmol 2 equiv.) via 
dropping funnel the reaction mixture turns orange and solidifies. Subsequently a 
solution of 2,6-dimethoxytoluene (60.00 g, 394 mmol, 1 equiv.) in benzene (260 
mL) was added to the orange residue at 0 °C within 15 min resulting in a deep 
red solution. After 30 min at that temperature the reaction mixture was quenched 
by pouring it into ice cold HCl (5%, 100mL). The aq. layer was washed with DCM 
(4 x 20 mL). The combined organic layers were dried over MgSO4, filtered and 
the solvent was evaporated. Purification by distillation under high vacuum gave 
30.22g (98 %) 179 as pale yellow oil. 
C11H14O3; 194.23 g/mol; 
Rf.: 0.64 (hexane : ethyl acetate = 4 : 1); 
1H NMR (CDCl3, 250 MHz): δ [ppm] = 7.62 (d, J = 8.8 Hz, 1 H), 6.68 (d, 
J = 8.8 Hz, 1 H), 3.87 (s, 3 H), 3.75 (s, 3 H), 2.62 (s, 3 H), 2.16 (s, 3 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 198.9, 162.1, 159.3, 128.9, 125.5, 120.2, 
105.9, 61.8, 55.7, 30.3, 8.9; 
HRMS (70 eV, 30 °C) calc.: m/z 194.0943, found 194.0951. 
 
2,4‐Dimethoxy‐3‐methylphenyl acetate (127) 
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A solution of 179 (30.22 g, 156 mmol, 1 equiv.) and pTsOH (208 mg, 1.29 
mmol, 0.007 equiv.) in DCM (35 mL) was treated with a suspension of mCPBA 
(57.57 g, 234 mmol, 1.5 equiv.) in DCM (280 mL) at 0 °C via dropping funnel 
within one hour. The resulting yellow suspension was allowed to warm to r.t. over 
night. After the addition of a saturated NaHSO3 solution (15 mL) the reaction 
mixture was vigorously stirred for 15 min, followed by the addition of sat. NaHCO3 
solution (15 mL) and additional 15 min of stirring. The aq. layer was extracted 
with DCM (3 x 100 mL). Consecutively the combined organic layers were washed 
with sat. NaHCO3 solution (100 mL) and water (100 mL), dried with Na2SO4. 
Evaporation of the solvent and purification by high vacuum distillation yielded 
22.29 g of 127 (68 %) as pale yellow oil. 
C11H14O4; 210.23 g/mol; 
Rf.: 0.84 (hexane : ethyl acetate = 4 : 1); 
1H NMR (CDCl3, 250 MHz): δ [ppm] = 6.87 (d, J = 8.8 Hz, 1 H), 6.61 (d, 
J = 8.8 Hz, 1 H), 3.81 (s, 3 H), 3.74 (s, 3H), 2.32 (s, 3 H), 2.15 (s, 3H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 169.8, 156.3, 150.4, 137.5, 121.2, 119.7, 
105.5, 60.8, 55.7, 20.8, 9.18; 
HRMS (70eV, 30 °C): calc.: 210.0892, found: 210.0899. 
 
 
2,4‐Dimethoxy‐3‐methylphenol (180) 
 
To a solution of 127 (63.0 g, 299 mmol, 1 equiv.) in EtOH (820 mL), aq. 
KOH (120 mL, 10 M, 4 equiv.) was added accompanied by moderate warming of 
the reaction mixture. After one hour at room temperature water (400 mL) was 
added and EtOH was removed under reduced pressure. The resulting aqueous 
solution was extracted with DCM (100 mL), acidified to pH 1 with conc. HCl and 
again washed with DCM (3 x 100 mL). The combined organic layers were 
washed with water (100 mL) and dried over Na2SO4. Evaporation of the solvent 
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and distillation under high vacuum afforded 38.88 g (77 %) of orange phenol 180, 
which crystallized on standing. 
C9H12O3; 168.19 g/mol; 
Rf.: 0.51 (hexane : ethyl acetate = 4 : 1); 
1H NMR (CDCl3, 250 MHz): δ [ppm] = 6.76 (d, J = 8.8 Hz, 1 H), 6.53 (d, 
J = 8.8 Hz, 1 H), 5.41 (s, 3 H), 3.77 (s, 3 H), 2.17 (s, 3 H); 
13C NMR (CDCl3, 62.5 MHz): δ [ppm] = 152.1, 146.1, 143.1, 120.1, 111.8, 107.0, 
60.9, 56.2, 9.4; 
HRMS: calc.: 168.1898, found: 168.1894. 
 
 
1‐(Benzyloxy)‐2,4‐dimethoxy‐methylbenzene (128) 
 
Phenol 180 (1.0 g, 6 mmol, 1 equiv.) was dissolved in a mixture of 
THF/DMF 12/1 (13.5 mL). The resulting orange solution was cooled to 0 °C. After 
15 min sodium hydride (248 mg, 6 mmol, 1.05 equiv.) was added batch-wise 
under vigorous stirring. Benzyl bromide (740 µL, 6 mmol, 1.05 equiv) was 
continuously added via syringe within 5 min. Over night the reaction mixture was 
allowed to warm to room temperature, resulting in a beige solution the next day. 
The reaction was quenched by the addition of water (15 mL) turning the mixture 
from beige to purple. The aqueous layer was separated and extracted with 
hexane (3 x 20 mL). The combined organic layers were washed with water, dried 
over Na2SO4. After filtration and solvent removal via evaporation the crude 
product was purified by flash column chromatography (hexane : ethyl acetate = 
19 : 1) to provide 1.45 g (95 %) 128 as yellow oil 
C16H18O3; 251.31 g/mol; 
Rf.: 0.54 (hexane : ethyl acetate = 9 : 1); 
1H NMR (CDCl3, 62.5 MHz): δ [ppm] = 7.54 (m, 5 H), 6.91 (d, J = 8.9 Hz, 1 H), 
6.62 (d, J = 8.9 Hz, 1 H), 5.17 (s, 2 H), 4.03 (s, 1 H), 3.86 (s, 1 H) 2.44 (s, 3 H); 
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13C NMR (CDCl3, 100 MHz): δ [ppm] = 153.3, 149.4, 146.6, 138.0, 128.9, 128.1, 
127.7, 121.6, 112.5, 105.6, 72.0, 60.9, 56.3; 
HRMS (70eV, 50 °C): calc.: 258.1256, found: 258.1261. 
 
 
1‐(Benzyloxy)‐5‐bromo‐2,4‐dimethoxy‐3methylbenzene (108) 
 
A solution of 128 (17.52 g, 67 mmol, 1 equiv.) in THF (210 mL) was cooled 
to 0 °C. After 10 min N-bromosuccinimide (15 g, 81 mmol, 1.2 equiv.) was added 
batch-wise to the vigorously stirred reaction mixture. Conc. sulfuric acid (200 µL) 
was added, causing the color of the mixture to turn into deep orange. After 90 
min the reaction was quenched by addition of sat. aq. NaS2O3 solution in the 
cold. 15 min later the aq. layer was separated and extracted with hexane (3 x 60 
mL). The combined organic layers were washed with brine (100 mL) and water 
(50 mL) and finally dried over Na2SO4. Removal of the solvent and purification by 
flash column chromatography (hexane : ethyl acetate = 19 :1) yielded in 21.77 g 
(95 %) of bromine 108 as yellow oil. 
C16H17BrO3; 337.21 g/mol; 
Rf.: 0.56 (hexane : ethyl acetate = 9 : 1); 
1H NMR (CDCl3, 62.5 MHz): δ [ppm] = 7.38 (m, 5H), 7.00 (s, 1 H), 5.05 (s, 2 H), 
3.82 (s, 3 H), 3.76 (s, 3 H), 2.26 (s, 3H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 150.3, 149.3, 148.4, 137.1, 129.0, 128.4, 
127.8 127.7, 116.1, 111.0, 71.7, 60.8, 60.7, 10.5; 
HRMS (70eV, 50 °C): calc.: 336.0361, found: 336.0358. 
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1‐(Benzyloxy)‐5‐(bromomethyl)‐2,4‐dimethoxy‐3‐methylbenzene (156) 
 
To a solution of bromine 108 (4.21 g, 15 mmol, 1 equiv.) in THF (55 mL) 
was added drop wise t-BuLi (22.7 mL, 1.7 M in hexane) at -78 °C within 30 min. 
Upon the addition the initially bright yellow solution turned its color from orange 
over bright green and olive to brown. After 15 min DMF (5.8 mL, 74 mmol, 4.9 
equiv.) was added via syringe followed by additional 30 min of stirring at -78 °C. 
The reaction mixture was diluted with ethyl acetate (50 mL) and quenched by the 
addition of brine (50 mL) at -78 °C. The resulting biphasic mixture was warmed to 
room temperature. The organic layer was washed with brine (20 mL) and water 
(20 mL) followed by drying over Na2SO4. Removal of the solvent provided 4.21 g 
of 155 as yellow oil. The crude product, which should be stored at -20 °C and 
under exclusion of sunlight, was used in the next step without further purification. 
C17H18O4; 286.32 g/mol; 
Rf.: 0.31 (hexane : ethyl acetate = 3 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] =10.28 (s, 1 H), 7.45 (m, 2 H), 7,38 (m, 2 H), 
7.33 (m, 1 H), 5.10 (s, 2 H), 3.92 (s, 3 H), 3.83 (s, 3 H), 2.23 (s, 3 H). 
 
Crude aldehyde 155 (3.81 g, 13 mmol, 1 equiv.) was dissolved in ethanol 
(47 mL) and coled to 0 °C in the dark. Sodium borohydride (511 mg, 13 mmol, 1 
equiv) was added batch-wise to the vigorously stirred yellow solution within 15 
min. After 30 min at 0 °C the reaction was quenched by cautious addition of sat. 
aq. ammonium chloride untill no more gas evolved. The resulting mixture was 
diluted with DCM (30 mL) and water (30 mL) was added 10 min later. The aq. 
layer was separated and extracted with DCM (3 x 20 mL). The combined organic 
layer was washed with pH 7 buffer (KH2PO4/Na2HPO4) and water (2 x 20 mL) 
and finally dried over Na2SO4. Filtration and subsequent evaporation of the 
solvent yielded 3.79 g of the crude alcohol. Exclusion of sunlight and storage at 
low temperature are necessary to avoid decomposition of the isolated product. 
C17H20O4; 288.34 g/mol; 
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Rf.: 0.78 (hexane : ethyl acetate = 3 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.45 (m, 2 H), 7.39 (m, 2 H), 7.32 (m, 1 H), 
6.84 (s, 1 H), 5.08 (s, 2 H), 4.65 (s, 2 H), 3.84 (s, 3 H), 3.73 (d, J = 0.81 Hz, 3 H), 
2.23 (s, 3 H). 
 
Imidazole (600 mg, 8.8 mmol, 1.2 equiv.) and triphenylphosphine (2.1 g, 
8.0 mmol, 1.1 equiv.) were dissolved in 24 mL dry DCM and cooled to 0 °C under 
Ar-atmosphere. Bromine (410 µL, 8.0 mmol, 1.1 equiv.) was added drop wise via 
syringe, allowing the reaction mixture to discolor after each drop. After 15 min the 
addition was finished and the pale orange reaction mixture was allowed to stir for 
additional 15 min at 0 °C. Subsequently, a solution of prior obtained alcohol (2.10 
g, 7.3 mmol, 1 equiv.) in 24 mL of dry DCM was added within 10 min. After 30 
min the alcohol was fully converted and the reaction was quenched with sat. aq. 
sodium thiosulfate solution (20 mL) and diluted with DCM (20 mL). The separated 
organic layer was washed with sat. aq. sodium thiosulfate (30mL), brine (30 mL) 
and finally with water (30 mL) and was dried over Na2SO4. After evaporation of 
the solvent, the resulting crude mixture was dissolved in a minimum amount of 
acetone and triphenylphosphine oxide was removed by the addition of hexane 
and filtration of the suspension through Celite®. Evaporation of the solvent 
yielded 2.485 g (96%) of bromide 156. 
C17H19BrO3; 351.24 g/mol; 
Rf.: 0.75 (hexane : ethyl acetate = 4 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.39 (m, 5 H), 6.84 (s, 1 H), 5.08 (s, 2 H), 
4.55 (s, 2 H), 3.85 (s, 3 H), 3.82 (s, 3 H), 2.22 (s, 3 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 152.9, 150.4, 145.6, 138.8, 129.0, 128.3, 
127.8, 126.4, 126.0, 113.9, 71.5, 61.5, 60.8, 29.4, 10.1; 
HRMS (70eV, 50 °C): calc.: 350.0518, found: 350.0522. 
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3‐Methoxy‐4‐(triisopropylsilyloxy)benzaldehyde (181) 
 
DMF (1.3 mL) was added to a mixture of vanillin (139) (250 mg, 1.64 
mmol, 1 equiv.) and imidazole (336 mg, 4.9 mmol, 3 equiv.). At 0 °C 
triisopropylsilyl chloride (520 mL, 2.46 mmol, 1.5 equiv.) was added drop wise via 
syringe. After 5 min the ice bath was removed and the reaction mixture was 
stirred at room temperature for 2 hours. DCM (10 mL) was added and the 
resulting organic layer was washed with water (3 x 10 mL) and brine (10 mL) and 
was dried with Na2SO4. After filtration, evaporation of the solvent, and purification 
by flash column chromatography (hexane : ethyl acetate = 9 : 1) 487 mg (96%) of 
silyl ether 181 were obtained as yellow oil. 
C17H28O3Si; 308.49 g/mol; 
Rf.: 0.39 (hexane : ethyl acetate = 5 : 1); 
1H NMR (CDCl3, 250 MHz): δ [ppm] = 9.83 (s, 1 H), 7.39 (d, J = 1.80 Hz, 1 H), 
7.35 (dd, J = 7.96 Hz, 1 H), 6.98 (d, J = 7.96 Hz, 1 H), 3.87 (s, 3 H), 1.27 (m, 
3 H), 1.08 (m, 18 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 191.4, 152.3, 152.0, 131.0, 126.6, 120.6, 
110.5, 55.8, 18.22, 13.3; 
HRMS (70 eV, 30 °C): calc.: 108.1808, found: 108.1811. 
 
 
3‐Methoxy‐4‐(triisopropylsilyloxy)phenol (140) 
 
To a solution of aldehyde 181 (9.833 g, 31.8 mmol, 1 equiv.) in DCM (60 
mL) was added batch-wise mCPBA (9.168 g, 48 mmol, 1.5 equiv.) at room 
temperature within 15 min, increasing the temperature of the reaction mixture to 
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approximately 40 °C. After 30 min of reaction time the starting material was fully 
consumed and the solvent was removed under reduced pressure. The resulting 
yellow residue was redissolved in 50 mL of ethyl acetate, washed with sat. aq. 
sodium bicarbonate solution (30 mL) and brine (30 mL). The organic layer was 
dried over Na2SO4, filtered and again evaporated. The resulting yellow oil was 
dissolved in methanol (40 mL) and treated with sodium carbonate (675 mg, 6.4 
mmol, 0.2 equiv.), whereby the reaction mixture turned its appearance from a 
yellow solution to a pink suspension. Again, the solvent was evaporated after 45 
min under vigorous stirring. The pink residue was dissolved in water (50 mL) and 
neutralized with 5% HCl followed by extraction with ethyl acetate (3 x 50 mL). 
The combined organic layer were dried with Na2SO4, filtered and concentrated 
under reduced pressure yielding 9.11 g (97 %) crude white crystals of desired 
phenol 140 after purification by flash column chromatography (hexane : ethyl 
acetate = 9 : 1 ). 
C16H28O3Si; 296.48 g/mol; 
Rf.:0.39 (hexane : ethyl acetate = 5 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 6.71 (d, J = 8.5 Hz, 1 H), 6.40 (d, 
J = 2.9 Hz, 1 H), 6.24 (dd, J = 8.5, 2.9 Hz, 1H), 4.35 (br, 1 H), 3.77 (s, 1 H), 1.22 
(m, 3 H), 1.09 (br, 10 H), 1.07 (br, 8 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 185.9, 150.5, 148.6, 129.9, 120.7, 106.5, 
101.0, 55.8, 18.3, 13.2; 
HRMS (70 eV, 30 °C): calc.: 296.1808, found: 296.1806. 
 
 
Triisopropyl(2‐methoxy‐4‐(methoxymethoxy)phenoxy)silane (182) 
 
Phenol 140 (222 mg, 0.75 mmol, 1 equiv.) was dissolved in DMF (3 mL) 
and sodium hydride (60 w% suspension in mineral oil, 45 mg , 1.13 mmol, 1.5 
equiv.) was added at room temperature. The two necked round-bottomed flask 
was equipped with a septum and cooled to 0 °C. After 15 min at that temperature 
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methoxymethyl chloride (90 µL, 1.13 mmol, 1.5 equiv.) was added within 5 min. 
The resulting reaction mixture was warmed to room temperature and stirred for 
another 7 hours. The reaction was quenched by the addition of pH 7 buffer 
(KH2PO4/Na2HPO4, 5 mL) and diluted with hexane (10 mL). The aqueous layer 
was extracted with hexane (3 x 10 mL). The combined organic layer was washed 
with brine (10 mL), water (10 mL) and was dried over Na2SO4. After filtration, 
removal of the solvent and purification by flash column chromatography (hexane : 
ethyl acetate = 5 : 1) 184 mg (72%) 182 were obtained as yellow oil. 
C18H32O4Si; 340.53 g/mol; 
Rf.: 0.64 (hexane : ethyl acetate = 5 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 6.76 (d, J = 8.7 Hz, 1 H), 6.57 (d, 
J = 2.8 Hz, 1 H), 6.48 (dd, J = 8.7, 2.8 Hz, 1 H), 5.10 (s, 2 H), 3.78 (s, 3 H), 3.02 
(s, 3 H), 1.23 (m, 3 H), 1.11 (br, 10 H), 1.08 (br, 8 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 152.4, 151.7, 140.9, 120.5, 107.6, 102.6, 
95.7, 56.3, 55.8, 18.3, 13.2; 
HRMS (70eV, 30 °C): calc.: 340.2070, found: 340.2073. 
 
 
Triisopropyl(2‐methoxy‐4‐(methoxymethoxy)‐3‐methylphenoxy)silane 
(141) 
 
Methyl ether 182 (6.346 g, 18.6 mmol, 1.0 equiv.) dissolved in THF (90 
mL) was cooled to -10 °C; n-BuLi (22.4 mL, 2.5 M in hexane, 5.0 equiv.) was 
added drop wise to the vigorously stirred solution, accompanied by changing 
from a colorless to a yellow solution. The resulting reaction mixture was stirred at 
-10 °C for one hour and was subsequently cooled to -78 °C followed by 
continuous addition of methyl iodide (4.7 mL, 74.5 mmol, 4.0 equiv.) within 10 
min resulting in a yellow solution. After 30 min -78 °C the reaction was warmed to 
room temperature. Finally sat. aq. ammonium chloride (20 mL) was added and 
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the separated organic layer was washed with brine (20 mL) and water (20 mL). 
The organic layer was dried over Na2SO4, filtered and concentrated under 
reduced pressure. Purification by flash column chromatography gave 5.768 g 
(87%) of the desired methylated species 141. 
C19H34O4Si; 344.56 g/mol; 
Rf.: 0.77 (hexane : ethyl acetate = 5 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 6.67 (d, J = 9.0 Hz, 1 H), 6.63 (d, 
J = 9.0 Hz, 1 H), 5.11 (s, 2 H), 3.78 (s, 3 H), 3.49 (s, 3 H), 2.17 (s, 3 H), 1.26 (m, 
3 H), 1.12 (br, 10 H), 1.10 (br, 8 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 150.4, 150.0, 144.6, 117.6, 110.4, 102.6, 
95.8, 60.5, 56.4, 18.3, 13.2, 9.7; 
HRMS (70 eV, 30 °C): calc.: 354.2226, found: 354.2230. 
 
 
3‐Methoxy‐2‐methyl‐4‐(triisopropylsilyloxy)phenol (137) 
 
Compound 141 (1.02g, 2.9 mmol, 1.0 equiv.) was dissolved in dry DCM 
(12 mL) and cooled to -12 °C. Trimethylsilyl bromide (1.5 mL, 11.5 mmol, 4.0 
equiv.) was added within 5 min. After additional 30 min at -12 °C the reaction 
mixture was allowed to warm to 10 °C and was stirred at that temperature for 
another 90 min. The clear orange solution was quenched with sat. aq. sodium 
bicarbonate solution (20 mL) and was diluted with ethyl acetate 20 mL. The 
organic layer was again washed with bicarbonate solution (30 mL), dried over 
Na2SO4 and after removal of the solvent under reduced pressure, the crude 
product was purified by flash column chromatography (hexane : ethyl acetate = 
19 : 1) providing 0.675 g (76%) desired deprotected phenol 137 as pale yellow oil 
which crystallized on standing. 
C17H30O3Si; 310.50 g/mol; 
Rf.: 0.77 (hexane : ethyl acetate = 5 : 1); 
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1H NMR (CDCl3, 400 MHz): δ [ppm] = 6.59 (d, J = 8.7 Hz, 1 H), 6.41 (d, 
J = 8.7 Hz, 1 H), 4.46 (s, 1 H), 3.78 (s, 3 H), 2.17 (s, 3 H), 1.27 (m, 3 H), 1.11 (br, 
10 H), 1.10 (br, 8 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 150.0, 148.6, 143.5, 119.1, 117.6, 110.26, 
60.6, 18.3, 13.2, 9.4; 
HRMS (70 eV, 30 °C): calc.: 310.1964, found: 310.1965. 
 
 
Fmoc and Cbz-protected Garner’s Aldehyde were prepared according to 
literature from readily available L-serine over 5 steps with high yield. 42,43,44 
 
 
(R)‐(9H‐Fluoren‐9‐yl)methyl 4‐(hydroxyl(2‐hydroxy‐4‐methoxy‐3‐methyl‐5‐
(triisopropylsilyloxy)phenyl)methyl)‐2,2‐dimethyloxazolidine‐3‐
carboxylate (138) 
 
Methylmagnesium chloride (57 µL, 3.0 M in THF, 1.3 equiv.) was added to 
a vigorously stirred solution of 137 (50 mg, 0.16 mmol, 1.2 equiv.) in THF (300 
µL) within 5 min at room temperature. The resulting reaction mixture was cooled 
to 0 °C and Fmoc-protected Garner’s aldehyde 109 (47 mg, 0.13 mmol, 1.0 
equiv.) in DCM (200 µL) was added drop wise. The ice bath was removed and 
the reaction was stirred at room temperature over night. After 12 hours the 
reaction was diluted with DCM (5 mL) and quenched with sat. aq. ammonium 
chloride solution (5 mL). The aqueous layer was extracted with DCM (3 x 5 mL). 
The combined organic layer was washed with brine (10 mL) and water (10 mL), 
dried over Na2SO4 and concentrated under reduced pressure. Purification by 
flash column chromatography (gradient, hexane : ethyl acetate = 7:1 to 4:1) 
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yielded 63 mg (71 %) of desired product 138 as pale yellow foam at a 
diastereomeric ratio of 2.3:1 (according to NMR data). 
C38H51NO7Si; 661.90 g/mol; 
Rf.: 0.18 (hexane : ethyl acetate = 2 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.77 (m; 2 H), 7.59 (m, 2 H), 7.37 (m, 4 H), 
6.27 (s, 1 H), 4.84 (dd, J = 28.3, 9.0 Hz, 2 H), 4.48 (d, J = 7.0 Hz, 1 H), 4,25 (t, 
J = 3.6 Hz, 1 H), 4.2 (m, 1 H), 3.73 (s, 3 H), 3.48 (br, 2 H), 2.12 (s, 3 H), 1.22 (m, 
3 H), 1.06 (dd, J = 7.25, 3.6 Hz, 18 H), 0.86 (br, 3 H), 0.77 (br, 3 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 168.5, 156.3, 149.7, 148.4, 148.4, 143.6, 
143.5, 141.7, 141.6, 127.8, 126.0, 124.3, 124.1, 121.0, 120.1, 120.0, 118.3, 
117.0, 95.0, 80.3, 67.1, 65.3, 62.8, 60.0, 47.2, 25.7, 23.5, 17.9, 12.7, 8.9; 
HRMS (70 eV, 150 °C): calc.: 661.3435, found: 661.3412. 
 
 
(R)‐Benzyl 4‐((5‐(benzyloxy)‐2,4‐dimethoxy‐3‐
methylphenyl)(hydroxy)methyl)‐2,2‐dimethyloxazolidine‐3‐carboxylate 
(135) 
 
To a solution of aromatic bromide 108 (300 mg, 0.9 mmol, 1.25 equiv.) in 
THF (7 mL) n-BuLi was added drop wise (360 µL, 2.5 M in hexane, 1.3 equiv.) at 
-78 °C whereby the color of the reaction mixture changed from dark red to foggy 
yellow. After 30 min at low temperature the solution was transferred to a solution 
of Cbz-protected Garner’s aldehyde 134 (188 mg, 0.7 mmol, 1.0 equiv.) in THF (7 
mL) via syringe within 10 min. After full consumption of the aldehyde, DCM (20 
mL) and sat. aq. ammonium chloride solution (20 mL) were added to the reaction 
-78 °C. The separated aq. layer was extracted with ethyl acetate (3 x 10 mL) and 
the combined organic layer was washed with brine (20 mL) and water (20 mL). 
The organic layer was treated with Na2SO4, filtered and concentrated under 
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reduced pressure. The crude product was purified by flash column 
chromatography (gradient, hexane : ethyl acetate = 7:1 to 2:1) providing 279 mg 
(75%) 135 at a diastereomeric ratio of 2.1:1 (according to NMR-data) as pale 
yellow foam. 
C30H35NO7; 521.6014 g/mol; 
Rf.: 0.33, 0.32* (hexane : ethyl acetate = 2 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.44 (dd, J = 7.9, 1.1 Hz, 2 H), 7.34 (m, 
8 H), 7.01 (s, 1 H), 5.39* (br, 1 H), 5.25 (br, 1 H), 5.22 (d, J = 10.7 Hz, 2 H), 5.11* 
(d, J = 12.7 Hz, 2 H), 5.07 (br, 2 H), 5.05* (br, 2 H), 4.45* (br, 1 H), 4.33 (br, 1 H), 
3.85 (br, 2 H), 3.83 (s, 3 H), 3.35 (br, 3 H), 2.18 (br, 3 H), 1.73 (br, 3 H), 1.48 (br, 
3 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 148.2, 147.9, 137.1, 128.5, 128.4, 128.2, 
127.8, 127.4, 125.5, 110.1, 71.0, 69.6, 67.2, 63.6, 60.7, 60.2, 32.2, 26.0, 23.6, 
9.5; 
(*) denotes the minor diastereomer 
HRMS (70 eV, 140 °C): calc.: 521.2415, found: 521.2424. 
 
 
(R)‐(9H‐Fluoren‐9‐yl)methyl 4‐((5‐(benzyloxy)‐2,4‐dimethoxy‐
3methylphenyl)(hydroxyl)methyl)‐2,2‐dimethyloxazolidine‐3‐carboxylate 
(136) 
 
136 was prepared according to the experimental procedure for 135 except 
the solvent was changed from THF to toluene. Oxazoldine 136 was obtained with 
excellent yield (96%) at a diastereomeric ratio of 2.7 : 1 according to NMR data. 
C37H39NO7; 609.71 g/mol; 
Diastereomer A: 
Rf.: 0.32 (hexane : ethyl acetate = 2 : 1);  
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1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.76 (d, J = 7.5 Hz, 2 H), 7.56 (m, 2 H), 
7.44 (m, 2 H), 7.38 (m, 4 H), 7.31 (m, 2 H), 6.96 (br, 1 H), 5.28 (br, 1 H), 5.06 (m, 
2 H), 4.79 (br, 1 H), 4.31 (br, 1 H), 4.24 (br, 1 H), 3.89 (m, 1 H), 3.81 (s, 3 H), 
3.74 (br, 2 H), 3.61 (m, 1 H), 3.36 (br, 1 H), 3.23 (br, 1 H), 2.18 (s, 3 H), 1.72 (m, 
2 H), 1.53 (m, 1 H), 0.75 (s, 3 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 149.8, 148.2, 147.9, 143.8, 141.5, 137.2, 
128.5, 128.4, 127.8, 127.7, 127.3, 127.1, 125.4, 124.2, 119.9, 110.1, 71.0, 69.1, 
66.6, 66.4, 64.3, 63.4, 62.1, 60.6, 60.4, 60.3, 47.3, 30.6, 25.2, 23.0, 19.1, 9.5. 
Diastereomer B: 
Rf.: 0.30 (hexane : ethyl acetate = 2 : 1);  
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.77 (dd, J = 7.3, 2.1 Hz, 2 H), 7.60 (dd, 
J = 10.9, 7.3, 2 H), 7.43 (m, 2 H), 7.37 (m, 4 H), 7.31 (m, 2 H), 6.82 (s, 1 H), 5.05 
(m, 2 H), 4.83 (m, 3 H), 4.27 (br, 1 H), 4.16 (br, 1 H), 3.81 (m, 3 H), 3.70 (br, 3 H), 
3.44 (m, 2 H), 2.19 (s, 3 H), 0.96 (br, 3 H), 0.79 (br, 3 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 151.2, 148.9, 148.8, 144.2, 144.1, 142.1, 
142.0, 137.6, 129.7, 128.9, 128.2, 127.9, 127.7, 127.6, 126.2, 124.8, 124.6, 
120.5, 120.4, 111.3, 95.3, 73.8, 71.5, 67.5, 65.4, 64.2, 61.7, 60.7, 47.6, 26.6, 
23.8, 10.1 
HRMS (70 eV, 80 °C): calc.: 609.2727, found: 609.2719. 
 
 
(S)‐(9H‐Fluoren‐9‐yl)methyl 1‐(5‐(benzyloxy)‐2,4‐dimethoxy‐3‐
methylphenyl)‐3‐hydroxypropan‐2‐ylcarbamate (145) 
OBn
O
O OH
136
O
N
Fmoc
OBn
O
O
145
OH
HN
Fmoc
Et3SiH, TFA
DCM, -21 °C to r.t.
 
A round bottomed flask was charged with a solution of 136 (18 mg, 0.03 
mmol, 1.0 equiv.) in DCM (0.5 mL). Triethylsilane (27 µL, 0.16 mmol, 5.7 equiv) 
was added at room temperature and the resulting reaction mixture was cooled to 
-21 °C. Subsequently trifluoroacetic acid (13 µL, 0.16 mmol, 5.7 equiv.) was 
added drop wise via syringe and the reaction was stirred for 30 min at -21 °C. 
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After 4 hours at room temperature the starting material was fully consumed; the 
reaction was diluted with DCM (3 mL) and quenched with sat. aq. sodium 
bicarbonate solution (3 mL). The aq. layer was extracted with DCM (3 x 6 mL) 
and the resulting organic layer was dried over Na2SO4. After filtration, removal of 
the solvent under reduced pressure and purification by flash column 
chromatography (hexane:ethyl acetate = 4:1) 16 mg (98%) 145 were obtained as 
colorless foam. 
C34H35NO6; 553.65 g/mol; 
Rf.: 0.23 (hexane : ethyl acetate = 1 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.76 (m, 2 H), 7.56 (dd, J = 22.5, 7.4 Hz, 
2 H), 7.39 (m, 5 H), 7.30 (m, 3 H), 6.69* (s, 1 H), 6.60 (s, 1 H), 5.57 (m, 2 H), 
5.05* (s, 2 H), 5.03 (s, 2 H), 4.44 (m, 2 H), 4.35 (m, 2 H), 4.21 (m, 1 H), 4.14 (m, 
1 H), 3.84* (s, 3 H), 3.83 (s, 3 H), 3.74* (br, 3 H), 3.71 (br, 3 H), 2.83 (m, 2 H), 
2.25 (s, 3 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 156.5, 155.9, 151.1, 148.5, 143.9, 141.3, 
137.0, 128.5, 127.9, 127.8*, 127.7, 127.4*, 127.3, 127.0, 125.1, 125.0*, 120.0, 
113.7, 113.6, 113.5*, 71.1, 71.0, 68.0, 66.9, 66.8*, 60.6*, 60.3, 54.3, 51.1, 47.3*, 
47.2, 31.7, 31.3, 9.8; 
(*) denotes the minor rotamer; 
HRMS (70 eV, 150 °C): calc.:576.2362, found: 576.2350. 
 
 
(S)‐(9H‐Fluoren‐9‐yl)methyl 1‐(5‐(benzyloxy)‐2,4‐dimethoxy‐3‐
methylphenyl)‐3‐(triethylsilyloxy)propan‐2‐ylcarbamate (149) 
 
Primary alcohol 145 (97 mg, 0.18 mmol, 1.0 equiv.) was dissolved in dry 
DMF (1 mL) and DMAP (22 mg, 0.18 mmol, 1.0 equiv.) together with imdazole 
(30 mg, 0.44 mmol, 2.5 equiv.) were added at room temperature. Subsequently, 
triethylsilyl chloride (40 µL, 0.22 mmol, 1.25 equiv.) was added. The resulting 
reaction mixture was quenched with pH 7 phosphate buffer (5 mL, 
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KH2PO4/Na2HPO4) after complete consumption of starting material. The aq. layer 
was washed with DCM (3 x 10). Hereafter, the combined organic layer was dried 
over Na2SO4, filtered and evaporated. Purification by flash column 
chromatography (hexane : ethyl acetate = 2 : 1) gave 84 mg (73%) desired silyl 
ether 149. 
C40H49NO6Si; 667.91 g/mol; 
Rf.: 0.71 (hexane : ethyl acetate = 1 : 1); 
NMR-data considers only the major rotamer; 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.75 (d, J = 7.4 Hz, 2 H), 7.54 (dd, J = 7.4, 
1.6 Hz, 2 H), 7.42 (m, 2 H), 7.37 (m, 4 H), 7.29 (m, 2 H), 6.72 (s, 1 H), 5.03 (s, 
2 H), 4.28 (m, 2 H), 4.19 (m, 1 H), 3.89 (br, 1 H), 3.80 (s, 3 H), 3.73 (br, 3 H), 
3.62 (m, 2 H), 2.87 (m, 2 H), 2.25 (s, 3 H), 0.99 (m, 9 H), 0.63 (m, 6 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 156.4, 144.4, 141.7, 137.7, 128.9, 128.2, 
128.0, 127.8, 127.6, 127.4, 126.4, 125.6, 120.3, 114.2, 71.5, 67.0, 64.1, 61.0, 
60.7, 54.2, 47.6, 10.2, 7.2, 4.8; 
HRMS: calc.: 690.3227, found: 690.3222. 
 
 
(S)‐1‐(5‐(Benzyloxy)‐2,4‐dimethoxy‐3‐methylphenyl)‐3‐
(triethylsilyloxy)propan‐2‐amine (148) 
 
Compound 149 (17 mg, 0.03 mmol, 1.0 equiv.) in THF (0.3 mL) was 
treated with piperidine (0.1 mL) at 0 °C, resulting in a 20 vol% piperidine solution. 
Within two hours the starting material was completely consumed, the reaction 
was diluted with ethyl acetate (5 mL) and quenched by the addition of pH 7 
phosphate buffer (10 mL, KH2PO4/Na2HPO4); the aq. layer was separated and 
extracted four times with ethyl acetate (10 mL). The combined organic layers was 
washed with brine (5 mL) and water (5 mL), dried with Na2SO4, filtered and 
concentrated under reduced pressure. Purification by flash column 
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chromatography (hexane : ethyl acetate = 1:1) gave 8 mg (100%) secondary 
amine 148 as colorless residue. 
C25H39NO4Si; 445.67 g/mol; 
Rf.: 0.18 (hexane : ethyl acetate = 1 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.44 (dd, J = 7.3, 1.3 Hz, 2 H), 7.38 (dd, 
J = 7.3, 7.2 Hz, 2 H), 7.31 (m, 1 H), 6.66 (s, 1 H), 5.06 (s, 2 H), 3.83 (s, 3 H), 3.67 
(s, 3 H), 3.59 (dd, J = 9.8, 4.5 Hz, 1 H), 3.47 (dd, J = 9.8, 6.6 Hz, 1 H), 3.13 (m, 
1 H), 2.76 (dd, J = 13.5, 5.0 Hz, 1 H), 2.52 (dd, J = 13.5, 8.4 Hz, 1 H), 2.22 (s, 
3 H), 0.96 (t, J = 7.9 Hz, 9 H), 0.61 (q, J = 0.79 Hz, 6 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 151.8, 151.2, 148.5, 136.9, 128.9, 128.2, 
127.8, 127.05, 126.0, 114.2, 71.5, 67.5, 61.0, 60.7, 54.2, 34.7, 10.1, 7.2, 4.8; 
HRMS: calc.: 445.2648, found: 445.2653. 
 
 
(S)‐(9H‐Fluoren‐9‐yl)methyl 1‐(5‐hydroxy‐2,4‐dimethoxy‐3‐methylphenyl)‐
3‐(triethylsilyloxy)propan‐2‐ylcarbamate (151) 
 
Silyl ether 149 (60 mg, 0.09 mmol, 1.0 equiv.) was dissolved in a 3:2 
methanol:ethyl acetate mixture (5 mL) before palladium hydroxide on charcoal 
(10 mg, 20 w%) was added to a Parr hydrogenation apparatus. The resulting 
black suspension was treated for two days under 3.4 bar hydrogen pressure. The 
catalyst was removed by filtration over a bulk of Celite®, removal of the solvent 
under reduced pressure followed by flash column chromatography (gradient, 
hexane : ethyl acetate = 5:1 to 1:1) yielded 31 mg (60%) of the desired product 
159 as colorless residue. 
C33H43NO6Si; 577.78 g/mol; 
Rf.: 0.25 (DCM : MeOH = 12 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.75 (d, J = 7.5 Hz, 2 H), 7.54 (d, 
J = 7.4 Hz, 2 H), 7.39 (dddd, J = 7.5, 7.4, 2.5, 0.8 Hz, 2 H), 7.29 (ddd, J = 7.5, 
2.5, 1.2 Hz, 2 H), 6.7 (s, 1H), 5.53 (d, J = 7.6 Hz,1 H), 5.39 (s, 1 H), 4.32 (dd, 
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J = 9.0, 6.2 Hz, 1 H), 4.20 (m, 2 H), 3.89 (br, 1 H), 3.74 (s, 3 H), 3.73 (s, 3H), 3.69 
(dd, J = 10.2, 2.6 Hz, 1 H), 3.59 (dd, J = 9.8, 5.2 Hz, 1 H), 2.85 (m, 1 H), 2.26 (s, 
3 H), 0.98 (t, J = 7.9 Hz, 9 H), 0.63 (q, J = 7.9 Hz, 6 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 156.0, 150.5, 145.1, 144.4, 144.1, 144.0, 
141.2, 127.6, 127.4, 127.0, 125.2, 125.1, 124.1, 119.9, 114.4, 66.6, 63.7, 60.7, 
60.6, 53.7, 47.2, 31.7, 29.7, 9.9, 6.8, 4.4; 
HRMS (eV, °C): calc.: 600.2757, found: 600.2748 (M + Na+). 
 
(S)‐(9H‐Fluoren‐9‐yl)methyl 4‐(5‐(benzyloxy)‐2,4‐dimethoxy‐3‐
methylbenzyl)‐2,2‐dimethyloxazolidine‐3‐carboxylate (147) 
 
Pure minor diastereomer B 136 (138 mg, 0.23 mmol, 1.0 equiv) together 
with carbon disulfide (270 µL, 4.47 mmol, 19.8 equiv.), dissolved in dry THF (5 
mL), was cooled to -78°C. After 15 min NaHMDS (270 µL, 0.27 mmol, 1.2 equiv.) 
was added drop wise and the resulting reaction mixture was stirred for an 
additional hour at -78 °C. Subsequently methyl iodide (140 µL, 0.23 mmol, 1.0 
equiv.) was added at -78 °C. After two hours the reaction mixture was quenched 
with sat. aq. ammonium chloride (5 mL); the aq. layer was extracted with ethyl 
acetate (3 x 5 mL). The separated and combined organic layer was washed with 
brine (10 mL) and water (10 mL), dried over Na2SO4 and evaporated under 
reduced pressure to afford 124 mg (80%) 146 as white foam after purification by 
flash column chromatography (hexane : ethyl acetate = 6 : 1). 
C39H41NO7S2; 699.88 g/mol; 
Rf.: 0.52 (hexane : ethyl acetate = 2 : 1); 
HRMS: calc.: 722.222, found: 722.2216 (M + Na+). 
The resulting white residue was dissolved (99 mg, 0.14 mmol, 1.0 equiv.) 
in toluene (5 mL), treated with tributyltin hydride (80 µL, 0.28 mmol, 2.0 equiv.) 
and AIBN (5 mg, 0.03 mmol, 0.2 equiv.) at room temperature. The mixture was 
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degassed by three pump-freeze-thaw cycles and heated to reflux for 16 hours. 
After concentration of the mixture at reduced pressure and purification by flash 
column chromatography (hexane : ethyl acetate = 20 : 1 and 2 : 1) 39 mg (46%) 
147 was obtained as white foam. 
C37H39NO6; 593.71 g/mol; 
Rf.: 0.51 (hexane : ethyl acetate = 2 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.75 (dd, J = 8.4, 8.3 Hz, 2 H), 7.63 (m, 
2 H), 7.37 (m, 8 H), 6.62* (s, 1 H), 5.02* (s, 2 H), 4.98 (d, J = 1.8 Hz, 2 H), 4.77* 
(d, J = 2.1 Hz, 2 H), 4.49 (ddd, J = 35.0, 10.8, 6.0 Hz, 2 H ), 4.26 (m, 1H), 4.09 
(m, 1 H), 3.82 (s, 3 H), 3.81* (s, 3 H), 3.72 (d, J = 2.6 Hz, 2H), 3.70* (s, 3 H), 
3.61* (ddd, J = 22.2, 8.8, 6.0 Hz, 2 H), 3.55 (s, 3 H), 3.04* (dd, J = 12.9, 1.9 Hz, 
1 H), 2.81 (dd, J = 13.3, 3.9 Hz, 1 H), 2.64 (dd, J = 12.9, 10.5 Hz, 1 H), 2.53* (dd, 
J = 12.3, 11.3 Hz, 1 H), 2.19 (s, 3 H), 1.66 (s, 3 H), 1.50* (s, 3 H), 0.96 (s, 3 H), 
0.82* (s, 3 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 153.5, 152.8, 152.4, 151.6, 148.1, 147.5, 
144.1, 141.6, 141.5* 141.4, 141.3*, 137.2, 128.4, 127.8, 127.7, 127,4, 127.2, 
127.1, 126.0, 125.8, 125.7, 125.1, 124.9*, 124.3, 124.2*, 120.0, 114.0, 113.9*, 
94.3, 93.6*, 71.2, 71.1*, 66.6, 66.4*, 66.0, 65.9*, 60.6*, 60.4, 60.3, 58.5*, 57.7, 
47.5, 47.3*, 33.5, 32.9*, 27.8, 26.8, 26.7, 26.6, 23.5*, 23.2*, 9.7; 
(*) denotes the minor rotamer; 
HRMS: calc.: 616.2675, found: 616.2681 (M + Na+). 
 
 
Phosphinate 165 was prepared in three steps according to literature, 
starting from readily available glyoxylic acid monohydrate.52 
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(Z)‐Methyl 3‐(5‐(benzyloxy)‐2,4‐dimethoxy‐3‐methylphenyl)‐2‐
(benzyloxycarbonylamino)acrylate (166) 
OBn
O
O
O
OBn
O
O
HN
O
O
Cbz
H
N
P
O
O
OEtO
OEt
Cbz
165
DBU
DCM, -21 °C to r.t.
166155  
Phosphinate 165 (130 mg, 0.23 mmol, 1.1 equiv.) in DCM (0.5 mL) was 
cooled to -21 °C followed by the drop wise addition of DBU (33 µL, 2.2 mmol,1.05 
equiv.) within 2 min. A solution of benzaldehyde 155 (60 mg, 0.21 mmol, 1.0 
equiv.) in DCM (0.5 mL) was added after 10 min at -21 °C. After one hour at 
-21°C the reaction mixture was warmed to room temperature for two hours before 
it was diluted with ethyl acetate (10 mL), quenched with sat aq. ammonium 
chloride solution (5 mL), dried (MgSO4) and concentrated under vacuum 
providing 43 mg (41 %) of the desired enamine 166 as white crystals. 
C28H29NO7; 491.53 g/mol; 
Rf.: 0.43 (hexane : ethyl acetate = 2 : 2); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.38 (m, 4 H), 7.31 (m, 6 H), 7.21 (s, 1 H), 
7.15 (br, 1 H), 6.93 (s, 1 H), 5.09 (s, 2 H), 4.97 (s, 2 H), 3.87 (s, 3 H), 3.81 (br, 
3 H), 3.61 (br, 3 H), 2.22 (s, 3 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 165.8, 153.8, 151.3, 149.6, 148.3, 136.8, 
135.9, 128.5, 128.4, 128.3, 128.2, 128.1, 127.9, 127.3, 126.0, 125.7, 124.3, 
121.9, 111.8, 70.9, 67.4, 66.9, 61.6, 60.4, 52.5, 9.5; 
HRMS: calc.: 514.1842, found: 514.1845 (M + Na+). 
 
N-(Diphenylmethylene)-glycine t-butyl ester (73) was prepared according 
to literature,50 except for the installation of the t-butyl ester, which was carried out 
in DCM with isobutene and cat. conc. H2SO4 from readily available L-glycine. 
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(S)‐t‐Butyl 2‐amino‐3‐(5‐(benzyloxy)‐2,4‐dimethoxy‐3‐
methylphenyl)propanoate (171) 
 
N-(Diphenylmethylene)-glycine tert-butyl ester (73) (400 mg, 1.35 mmol, 
1.0 equiv.), O-allyl-N-(9-anthracenylmethyl)cinchonidinium bromide (74) (82 mg, 
0.14 mmol, 0.1 equiv.) and cesium hydroxide monohydrate (2.497 g, 14.87 mmol, 
10.0 equiv.) were suspended in DCM (1.8 mL) in a three necked round-bottomed 
flask equipped with a large magnetic stirring bar under Ar-atmosphere, resulting 
in a bright yellow cake. The vigorously stirred reaction mixture was cooled to -78 
°C for 10 min before a solution of benzylic bromide 156 (522 mg, 1.48 mmol, 1.1 
equiv.) in DCM (1.8 mL) was added within 10 min. The reaction was warmed to 
-10 °C over 14 hours. Diethylether (10 mL) and water (10 mL) were added. The 
separated aq. layer was extracted with diethylether (3 x 10 mL) containing the 
product, and DCM (3 x 10 mL), only containing phase transfer catalyst 74. The 
combined ethereal layer was washed with brine (10 mL) and water (10 mL), dried 
and concentrated under vacuum, giving crude imine 170. To the resulting oil, 
diethylether (4 mL) and a 1 : 1 mixture of water and acetic acid (10 mL), was 
added. The organic layer was washed with water several times until no more 
amine was in the acidic aq. layer. The combined aq. layer was transferred to an 
Erlenmeyer flask and cautiously adjusted to pH 12 with solid sodium carbonate. 
The crude product precipitated as orange oil on the surface upon neutralization, 
DCM (30 mL) was added and the layers separated. The aqueous layer was 
extracted with DCM (3 x 30 mL). The combined organic layer was finally dried 
(MgSO4), filtered and concentrated under vacuum. Purification by flash column 
chromatography (DCM : methanol = 12 : 1 to 6:1) gave 469 mg (78%) of the 
desired secondary amine 171 of 88% ee (according to NMR data of Mosher’s 
amide 184, 186) as yellow oil. 
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Imine 170: 
C36H39NO5; 565.70 g/mol; 
Rf.: 0.60 (hexane : ethyl acetate = 4 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.64 (m, 2 H), 7.46 (m, 2 H), 7.31 (m, 9 H), 
7.23 (m, 2 H), 6.58 (s, 1 H), 4.75 (d, J = 11.6 Hz, 1 H), 4.63 (d, J = 11.6 Hz, 1 H), 
4.17 (dd, J = 10.0, 3.5 Hz, 1 H), 3.79 (s, 3 H), 3.45 (s, 3 H), 3.32 (dd, J = 13.3, 
3.5 Hz, 1 H), 3.02 (dd, J = 13.3, 10.1 Hz, 1 H), 2.17 (s, 3 H), 1.46 (s, 9 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 171.0, 169.9, 151.5, 147.7, 147.0, 139.5, 
137.3, 136.2, 130.1, 128.7, 128.4, 128.0, 127.8, 127.7, 127.2, 126.2, 125.1, 
114.3, 81.1, 70.7, 66.9, 60.7, 60.3, 33.5, 28.1, 9.5; 
HRMS: calc.: 566.2906, found: 566.2902 (M + H+). 
Amine 171: 
C23H31NO5; 401.50 g/mol; 
Rf.: 0.42 (DCM : MeOH = 12 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.44 (dd, J = 7.4, 1.1 Hz, 2 H), 7.34 (ddd, 
J = 7.4, 7.0, 0.8 Hz, 2 H), 7.31 (ddd, J = 7.0, 1.3, 0.8 Hz, 1 H), 6.67 (s, 1 H), 5.05 
(s, 2 H), 3.83 (s, 3 H), 3.69 (s, 3 H), 3.62 (dd, J = 8.6, 5.5 Hz, 1 H), 3.00 (dd, 
J = 13.5, 5.5 Hz, 1 H), 2.70 (dd, J = 13.5, 8.6 Hz, 1 H), 2.22 (s, 3 H), 1.47 (br, 
2 H),1.42 (s, 9 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 174.6, 151.6, 148.0, 147.4, 137.3, 132.1, 
132.1, 128.5, 127.8, 127.4, 125.7, 125.6, 113.9, 80.9, 71.1, 60.6, 60.3, 55.7, 
36.1, 28.0, 9.7; 
HRMS: calc.: 401.2202, found: 401.2207. 
 
 
(S)‐t‐Butyl 3‐(5‐(benzyloxy)‐2,4‐dimethoxy‐3‐methylphenyl)‐2‐((S)‐3,3,3‐
trifluoro‐2‐methoxy‐2‐phenylpropanamido)propanoate (184) 
 
67 | P a g e  
 
Secondary amine 171 (10 mg, 0.025 mmol, 1.0 equiv.) was suspended in 
DCM and cooled to 0 °C. Triethylamine (8 µL, 0.055 mmol, 2.2 equiv.) was added 
drop wise and 10 min later (R)-(-)-α-methoxy-α-(trifluoromethyl)phenylacetyl 
chloride 183 (5 µL, 0.028 mmol, 1.1 equiv.). The reaction mixture was warmed to 
room temperature and stirred for 15 min. Removal of the solvent and base under 
vacuum gave 14 mg (91%) of crude corresponding Mosher amide 184.  
C33H38F3NO7; 617.65 g/mol; 
Rf.: 0.33 (hexane : ethyl acetate = 2 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.74 (d, J = 7.7 Hz, 2 H), 7.56 (m, 2 H), 
7.38 (m, 6 H), 6.69 (s, 1 H), 5.03 (s, 2 H), 4.63 (m, 1 H), 3.81 (s, 3 H), 3.67 (s, 
3 H), 3.25 (s, 3 H), 3.07 (dd, J = 13.9, 8.5 Hz, 1 H), 3.00 (dd, J = 13.9, 5.5 Hz, 
1 H), 2.21 (s, 3 H), 1.38 (s, 9 H); 
NMR data only considers the major diastereomer. 
HRMS: calc.: 640.2498, found: 640.2409. 
 
 
(R)‐t‐Butyl 3‐(5‐(benzyloxy)‐2,4‐dimethoxy‐3‐methylphenyl)‐2‐((R)‐3,3,3‐
trifluoro‐2‐methoxy‐2‐phenylpropanamido)propanoate (186) 
OBn
O
O
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186 was synthesized according to the procedure for 184 except 
(+)-Mosher chloride 185 was used instead of (-)-enantiomer. The reaction yielded 
15 mg (97%) crude product 186 as colorless oil. 
C33H38F3NO7; 617.65 g/mol; 
Rf.: 0.33 (hexane : ethyl acetate = 2 : 1); 
1H NMR (CDCl3, 100 MHz): δ [ppm] = 7.81 (d, J = 7.2 Hz, 2 H), 7.61 (m, 2 H), 
7.36 (m, 6 H), 6.62 (s, 1 H), 4.94 (s, 2 H), 4.64 (m, 1 H), 3.81 (s, 3 H), 3.58 (s, 
3 H), 3.44 (s, 3 H), 3.12 (ddd, J = 14.0, 7.1, 2.2 Hz, 2 H), 2.13 (s, 3 H), 1.41 (s, 
9 H); 
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NMR data only considers the major diastereomer. 
HRMS: calc.: 640.2498, found: 640.2411. 
 
 
(S)‐1‐(5‐(Benzyloxy)‐2,4‐dimethoxy‐3‐methylphenyl)‐3‐(t‐
butyldimethylsilyloxy)propan‐2‐amine (150) 
OBn
O
O
NH2
O
163
OtBu
OBn
O
O
NH2
OTBS
141
1) LAH, THF, 0 °C
2) NEt3, DMAP, TBSCl,
DCM, r.t.
 
To amine 171 (389 mg, 1.0 mmol, 1.0 equiv) in THF (10 mL) was added 
LAH (480 µL, 4.0 M in THF, 2.0 equiv) at 0 °C within 5 min. The resulting pale 
yellow reaction mixture was quenched by addition of sat. aq. sodium thiosulfate 
solution (10 mL) after 15 min and complete consumption of starting material. The 
aq. layer was extracted with DCM (4 x 10 mL) and the combined organic layer 
was washed with brine (10 mL) and water (10 mL), dried (MgSO4), filtered and 
concentrated under vacuum, affording 338 mg of crude alcohol. 
The crude product was dissolved in DCM (6 mL) and triethylamine (170 µl, 2.1 
mmol, 2.2 equiv.) was added at room temperature. DMAP (194 µL, 0.2 mmol, 
0.22 equiv.) and a solution of TBSCl (165 mg, 1.1 mmol, 1.1 equiv.) in DCM (6 
mL) were added consecutively under vigorous stirring. The resulting reaction 
mixture was stirred for 14 hours, quenched by the addition of water (10 mL) and 
the aq. layer was washed with DCM (3 x 10 mL). The combined organic layer 
was washed with brine (15 mL), dried (MgSO4), filtered and evaporated. 
Purification by flash column chromatography (gradient, DCM : MeOH = 39 : 1 to 
10 : 1) yielded 299 mg (69%) of 150 as pale yellow oil. 
C25H39NO4Si; 445.67 g/mol; 
Rf.: 0.68 (DCM : MeOH = 12 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.46 (m, 2 H), 7.37 (m, 2 H), 7.31 (m, 1 H), 
6.66 (s, 1 H), 6.62* (s, 1 H), 5.06 (s, 2 H), 5.02* (s, 2 H), 3.83 (s, 3 H), 3.82* (s, 
3 H), 3.69* (s, 3 H), 3.67 (s, 3 H), 3.56 (dd, J = 9.7, 4.6 Hz, 1 H), 3.45 (dd, 
J = 9.7, 6.3 Hz, 1 H), 3.08 (m, 1 H), 2.74 (dd, J = 13.4, 5.0 Hz,1 H), 2.46 (dd, 
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J = 13.4, 8.6 Hz, 1 H), 2.22 (s, 3 H), 2.20* (s, 3 H), 1.58 (br, 2 H), 0.91 (s, 9 H), 
0.88* (s, 9 H), 0.06 (d, J = 1.6 Hz, 6 H), 
(*) denotes the minor rotamer; 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 151.4, 148.0, 147.1, 137.3, 128.5, 127.8, 
127.3, 127.0, 125.6, 113.8, 71.1, 67.8, 60.6, 60.3, 53.7, 34.7, 25.9, 18.3, 9.7, 
-5.3; 
HRMS: calc.: 446.2727, found: 446.2721 (M + H+). 
 
 
1‐Bromo‐2,4‐dimethoxy‐5‐(methoxymethoxy)‐3‐methylbenzene (188) 
 
187 (1.50 g, 7.0 mmol, 1.0 equiv) was dissolved in acetonitrile (35 mL) and 
N-bromosuccinimide (1.32 g, 7.4 mmol, 1.05 equiv.) was added batch-wise at 
0 °C. The reaction mixture was stirred at 0°C for three hours, diluted with ethyl 
acetate (10 mL) and quenched with aq. sat. sodium thiosulfate solution (20 mL). 
The separated organic layer was washed with water (10 mL) and brine (10 mL), 
dried (MgSO4) and concentrated under reduced pressure to yield 2.038g (99 %) 
of 188 after purification by flash column chromatography (hexane : ethyl acetate 
= 10 : 1). 
C11H15BrO4; 291.14 g/mol; 
Rf.: 0.50 (hexane : ethyl acetate = 4 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.19 (d, J = 0.4 Hz, 1 H), 5.15 (s, 2 H), 
3.80 (s, 3 H), 3.75 (s, 3 H), 3.51 (s, 3 H), 2.24 (d, J = 0.4 Hz, 3 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 151.0, 148.7, 147.6, 127.7, 118.5, 111.3, 
96.0, 60.8, 60.7, 56.7, 10.5; 
HRMS (70 eV, 30 °C): calc.: 290.0154, found: 290.0148. 
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2,4‐Dimethoxy‐5‐(methoxymethoxy)‐3‐methylbenzaldehyde (189) 
 
Bromide 188 (2.038 g, 7.0 mmol, 1 equiv.) was dissolved in diethyl ether 
(24 mL), cooled to -78 °C and t-BuLi (10.3 mL, 1.7 M in hexane, 2.5 equiv.) was 
added within 15 min, where upon the reaction mixture turned its appearance from 
a blue solution to a beige suspension. After additional 30 min at -78 °C DMF (2.6 
mL, 33.6 mmol, 4.8 equiv.) was added drop wise resulting in a grey suspension 
which was stirred for additional 60 min; sat. aq. ammonium chloride solution (15 
mL) was added and the aq. layer was washed with DCM (3 x 20 mL). The 
combined organic layer was dried (MgSO4) and concentrated under vacuum 
providing 1.618 g (96 %) of 189 after purification by flash column chromatography 
(hexane : ethyl acetate = 14 : 1). 
C12H16O5; 240.25 g/mol; 
Rf.: 0.54 (hexane : ethyl acetate = 4 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 10.1 (s, 1 H), 7.09 (s, 1 H), 5.03 (s, 2 H), 
3.73 (s, 3 H), 3.66 (s, 3 H), 3.33 (s, 3 H), 2.05 (s, 3 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 189.0, 158.0, 154.8, 147.1, 126.4, 124.8, 
112.3, 95.3, 63.5, 60.5, 56.3, 9.1; 
HRMS (70 eV, 30 °C): calc.: 240.0998, found: 240.0991. 
 
 
(2,4‐Dimethoxy‐5‐(methoxymethoxy)‐3‐methylphenyl)methanol (190) 
 
Sodium borohydride (290 mg, 7.4 mmol, 1.1 equiv.) was added batch-wise 
to a solution of 189 (1.618 g, 6.6 mmol, 1.0 equiv) in ethanol (80 mL) at 0 °C. The 
resulting reaction mixture was stirred at 0 °C for two hours, diluted with diethyl 
ether and quenched with sat aq. ammonium chloride solution (30mL). The aq. 
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layer was extracted with diethyl ether (3 x 20 mL). The combined organic layer 
was dried (MgSO4), filtered and concentrated under reduced pressure. After 
purification by flash column chromatography (gradient, hexane : ethyl acetate = 
7 : 1 to 2:1) 1.593 g (98 %) benzylic alcohol 190 were obtained as yellow oil. 
C12H18O5; 242.27 g/mol; 
Rf.: 0.22 (hexane : ethyl acetate = 2 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 6.98 (s, 1 H), 5.17 (s, 2 H), 4.64 (d, 
J = 5.7 Hz, 2 H), 3.81 (s, 3 H), 3.73 (s, 3 H), 3.51 (s, 3 H), 2.21 (s, 3 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 151.7, 148.6, 146.7, 129.1, 125.8, 114.4, 
95.5, 61.3, 61.1, 60.4, 56.2, 9.4; 
HRMS (70 eV, 30 °C): calc.: 242.1154, found: 242.1130. 
 
 
1‐(Bromomethyl)‐2,4‐dimethoxy‐5‐(methoxymethoxy)‐3‐methylbenzene 
(174) 
 
Primary alcohol 190 (300 mg, 1.24 mmol, 1equiv.) and triphenylphosphine 
(373 mg, 1.42 mmol, 1.15 equiv.) were dissolved in DCM (13 mL) at room 
temperature and cooled to 0 °C. N-Bromosuccinimide (242 mg, 1.36 mmol, 1.10 
equiv.) was added in one portion. After 10 min the reaction was warmed to room 
temperature for 2 hours. Finally DCM (15 mL) and water (15 mL) were added. 
The organic layer was washed with brine (15 mL), filtered and concentrated 
under vacuum. The resulting residue was dissolved in a minimum amount of 
acetone, cold hexane was added to precipitate triphenylphosphine oxide, which 
was removed by filtration over a bulk of Celite®. Removal of the solvent resulted 
in 357 mg (94%) benzylic bromide 174. 
C12H17BrO4; 305.17 g/mol; 
Rf.: 0.79 (hexane : ethyl acetate = 2 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.01 (s, 1 H), 5.18 (s, 2 H), 4.54 (s, 2 H), 
3.82 (s, 3 H), 3.52 (s, 3 H), 2.21 (s, 3 H); 
72 | P a g e  
 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 152.2, 149.7, 146.8, 126.3, 126.1, 116.1, 
95.6, 61.0, 60.4, 56.3, 28.8, 9.7; 
HRMS: calc.: 446.2727, found: 446.2721 (M + H+). 
 
 
(S)‐t‐Butyl 2‐amino‐3‐(2,4‐dimethoxy‐5‐(methoxymethoxy)‐3‐
methylphenyl)propanoate (175) 
 
The asymmetric alkylation of benzylic bromide 174 and hydrolysis of the 
intermediary imine was performed according to the procedure for 171.  
The desired amine 175 was obtained at a yield of 99% and 88% ee (according to 
NMR data of the corresponding Mosher’s amide). 
Imine 191: 
C31H37NO6; 519.63 g/mol; 
Rf.: 0.49 (hexane :ethyl acetate = 4 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] =7.49 (m, 6H), 7.30 (m, 4 H), 6.71 (s, 1 H), 
4.91 (s, 2 H), 4.16 (dd, J = 9.9, 3.5 Hz, 1 H), 3.77 (s, 3 H), 3.45 (s, 3 H), 3.29 (dd, 
J = 13.3, 3.5 Hz, 1 H), 3.26 (s, 3 H), 3.01 (dd, J = 13.3, 9.9 Hz, 1 H), 2.17 (s, 
3 H), 1.45 (s, 9 H); 
HRMS: calc.: 542.2519, found: 542.2527 (M + Na+). 
Amine 175: 
C18H29NO6; 355.43 g/mol; 
Rf.: 0.39 (DCM : MeOH = 12 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 6.82 (s, 1 H), 5.15 (dd, J = 7.6, 6.6 Hz, 
2 H), 3.80 (s, 3 H), 3.69 (s, 3 H), 3.65 (dd, J = 8.6, 5.6 Hz, 1 H), 3.51 (s, 3 H), 
2.98 (dd, J = 13.6, 5.6 Hz, 1 H), 2.74 (dd, J = 13.6, 8.6 Hz, 1 H), 2.21 (s, 3 H), 
1.52 (br, 2 H), 1.42 (s, 9 H); 
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13C NMR (CDCl3, 100 MHz): δ [ppm] = 174.6, 152.4, 147.9, 146.5, 126.2, 125.6, 
116.2, 95.7, 80.9, 60.5, 60.4, 56.2, 56.7, 36.1, 28.0, 9.7; 
HRMS: calc.: 355.1995, found: 355.1988. 
 
 
(S)‐5‐(2‐Amino‐3‐(t‐butyldimethylsilyloxy)propyl)‐2,4‐dimethoxy‐3‐
methylphenol (152) 
 
Secondary amine 150 (238 mg, 0.5 mmol, 1.0 equiv.) and t-butanol (0.8 
mL, 8.4 mmol, 15.7 equiv.) were dissolved in 1.2 mL THF. At -78 °C 
approximately 8 mL ammonia were condensed to the reaction mixture. Lithium (8 
mg, 1.2 mmol, 2.2 equiv.) was added to the vigorously stirred solution. After one 
hour solid ammonium chloride was added and the reaction mixture was allowed 
to warm to room temperature. The resulting solution was concentrated and the 
resulting residue was purified by flash column chromatography (gradient, DCM : 
methanol = 24 : 1 to 3 : 1). The purification gave 70 mg (31 %) of the desired 
compound 152 and starting material (69%) was recovered. 
C18H39NO4Si; 355.54 g/mol; 
Rf.: 0.37 (DCM : MeOH = 12 : 1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 6.65 (s, 1 H), 3.78 (s, 3 H), 3.66 (d, 3 H), 
3.60 (dd, J = 9.8, 4.8 Hz, 1 H), 3.48 (dd, J = 9.8, 6.3 Hz, 1H), 3.12 (m, 1 H), 2.73 
(dd, J = 13.5, 5.1 Hz, 1 H), 2.50 (dd, J = 13.5, 8.6 Hz, 1 H), 2.23 (s, 3 H), 0.91 (s, 
9 H), 0.64 (d, J = 2.7 Hz, 6 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 150.5, 145.2, 144.4, 128.1, 124.4, 114.1, 
67.6, 60.7, 60.6, 53.6, 34.3, 25.9, 16.9, 9.9, -5.4; 
HRMS: calc.: 356.2257, found: 356.2249 (M + H+). 
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(1R,3S)‐1‐(Benzyloxymethyl)‐3‐((t‐butyldimethylsilyloxy)methyl)‐5,7‐
dimethoxy‐6‐methyl‐1,2,3,4‐tetrahydroisoquinolin‐8‐ol (173) 
 
A suspension of amino phenol 152 (60 mg, 0.17 mmol, 1.0 equiv.), 
crushed 4 Å molecular sieves (20 mg) and acetic acid (2.4 µL, 0.04 mmol, 0.25 
equiv.) in DCM (2 mL) was degassed by four freeze-pump-thaw cycles. 
Benzyloxy acetaldehyde 99 (29 mg, 0.19 mmol, 1.1 equiv.) dissolved in 
degassed DCM (1 mL) was added to the vigorously stirred suspension via 
syringe pump within 8 hours at room temperature. The reaction was stirred for 24 
hours, whereupon its color changed from beige to dark brown. The suspension 
was diluted with DCM (4 mL), filtered and cautiously treated with sat. aq. sodium 
bicarbonate solution (5 mL). The aq. layer was washed with DCM (4 x 5 mL). The 
combined organic layer was dried (MgSO4), filtered and concentrated under 
vacuum. Purification by flash column chromatography (DCM : MeOH : 60 : 1 to 
20 : 1) yielded 82 mg (99%) of tetrahydroisoquinoline 173. 
C27H41NO5Si; 487.70 g/mol; 
Rf.: 0.45 (DCM : MeOH = 12 :1); 
1H NMR (CDCl3, 400 MHz): δ [ppm] = 7.30 (m, 5 H), 4.58 (dd, J = 20.0, 12.0 Hz, 
2 H), 4.50 (t, J = 4.5 Hz, 1 H), 4.13 (dd, J = 9.1, 4.7 Hz, 1 H), 3.77 (dd, J = 10.5, 
4.7 Hz, 1 H), 3.76 (s, 3 H), 3.69 (dd, J = 9.1, 6.0 Hz, 1 H), 3.65 (s, 3H), 3.63 (dd, 
J = 10.5, 6.9 Hz, 1 H), 2.86 (m, 1 H), 2.81 (dd, J = 15.3, 2.5 Hz, 1 H), 2.28 (dd, 
J = 15.3, 11.5 Hz, 1 H), 2.22 (s, 3 H), 1.27 (br, 1 H), 0.90 (s, 9 H), 0.08 (s, 6 H); 
13C NMR (CDCl3, 100 MHz): δ [ppm] = 149.2, 144.0, 143.0, 138.1, 128.3, 127.6, 
127.5, 125.9, 122.0, 74.5, 73.2, 67.1, 60.6, 60.2, 53.7, 27.1, 25.9, 18.3, 9.5, -5.3; 
HRMS: calc.: 487.2754, found: 487.2758. 
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